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general IntroductIon

General introduction
9
ch
ap
te
r 1Breast cancer is one of the leading causes of death of women in western countries. 
It affects one out of eight females in the USA (1) and one out of nine females in The 
Netherlands (www.kankerregistratie.nl) during their lifetime. Many risk factors for breast 
cancer have been identified including gender, familial susceptibility, age, and exposure 
to hormones i.e. use of exogenous hormones, young age at menarge, and high age at 
menopause and first pregnancy (2). Familial breast cancer accounts for 5-10% of total 
breast cancer. The remaining 90-95% are called “sporadic”. Occasionally breast cancer 
also affects males (1% of the breast-cancer incidence in women).
In The Netherlands there are approximately 12000 new cases and about 3300 deaths 
yearly as a result of the disease. Since 1994, the mortality has slightly decreased due 
to earlier detection, following the introduction of the national breast cancer-screening 
program, and better treatment strategies (http://www.rivm.nl). Breast cancer patients 
may be subjected to various treatments including surgery, radiation, chemotherapy, 
molecular targeted therapy, or endocrine (hormonal) therapy. Often treatment strategies 
are combined. Surgery forms a part of nearly every patient’s treatment for breast cancer, 
resulting in partial removal (lumpectomy) or total removal of the breast (mastectomy). 
Radiation may be used before or after surgery, and may accompany chemotherapy. In 
molecular targeted therapy, compounds like monoclonal antibodies or small tyrosine 
kinase inhibitors inhibit a specific target molecule. In contrast to conventional chemo-
therapy, which acts on all dividing cells generating toxic effects and damage of normal 
tissues, targeted drugs allow to hit, in a more specific manner, subpopulations of cells 
directly involved in tumor progression. Endocrine therapy works by interfering with the 
estrogen pathway that enhances cell-proliferation. It is applied for prevention, adjuvant 
therapy, and for treatment of metastatic cancers in patients with hormone receptor-
positive tumors (3, 4).
estrogens and theIr receptors
Estrogens are important regulators in the development of the normal breast, but also 
in breast cancer expansion and progression. More than a century ago, Scottish surgeon 
George Beatson noted that removal of the ovaries, which later was proven to cause 
reduction of endogenous estrogen levels, could induce breast cancers to regress. (5). 
In premenopausal women endogenous estrogens mainly originate from the ovaries. In 
postmenopausal women peripheral aromatization of adrenal androgens is their main 
resource. Estrogens perform their function by interacting with the estrogen receptors 
(ER). Two ER genes have been identified in mammals, ERα and ERβ, which show similar 
DNA- and ligand-binding properties, but distinct tissue distributions and functions (6-9). 
In ER signaling, there are several mechanisms of action: classical, ERE-independent, 
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ligand-independent, and nongenomic (Figure 1.1) (10-12). In the classical mechanism, 
upon ligand binding, the cytoplasmic receptor is translocated to the nucleus were it 
dimerizes, recruits co-activator proteins and general transcription factors, and activates 
genes with an estrogen responsive element (ERE). Most of these genes are involved in 
cell proliferation and survival or in maintaining tissue architecture (13-15). Ligand-bound 
ER can also modulate gene expression through interaction of the receptor with Fos and 
Jun at activator protein-1 (AP-1) binding sites (16), or with GC-box bound specificity 
protein 1 (SP-1) (ERE-independent) (17). In the ligand-independent mechanism, ER is 
phosphorylated by growth factors or signaling molecules leading to dimerization, DNA 
binding, and activation of transcription (18, 19). Activation of a membrane-associated 
form of ER causes rapid nongenomic effects of estrogen signaling (20, 21). In breast 
cancer ERα is highly expressed, which results in enhanced proliferation without differ-
entiation or apoptosis. In contrast, expression of ERβ declines with increasing tumor 
Figure 1.1 
 
 
 
Figure 1.2 
 
 
 
Figure 1.1 At least four mechanisms of estrogen-receptor (ER) signaling are known. A, the genomic, ligand-dependent, classical mechanism; 
Estradiol (E2)-bound ER dimers bind to EREs in target promoters, resulting in an up- or downregulation of gene transcription and subsequent 
estrogenic effects in the cell. B, the genomic, ligand-dependent, ERE-independent mechanism; Ligand-bound ER complexes bind to alternative 
response elements such as AP-1 through association with other DNA-bound transcription factors like Fos and Jun, upregulating gene 
transcription. C, the genomic, ligand-independent mechanism; Growth factors or signaling molecules (not shown) activate intracellular kinase 
pathways leading to phosphorylation (P) and activation of ER and subsequent target-gene transcription in a ligand-independent manner. D, the 
nongenomic, ligand-dependent mechanism; E2 binds to a possible membrane-associated form of ER, directly activating intracellular signaling 
cascades that generate rapid estrogenic effects in the cell. For simplification the roles of cofactors in ER signaling have been left aside in this figure. 
(Based on Figure 1 from ref 10)
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r 1aggressiveness (11). Nearly 70% of breast cancers are ERα positive and may be eligible 
for endocrine therapy.
therapeutIc agents for endocrIne therapy
The estrogen dependence of breast cancer represents a unique feature of the disease 
that can be manipulated to prevent tumor development and effectively control growth. 
The current strategy for treatment of hormone-dependent breast cancer is to inhibit 
estrogen synthesis or block the action of estrogen by ovarian ablation or application 
of endocrine therapy using selective estrogen receptor modulators (SERMs), selective 
estrogen receptor downregulators (SERDs), luteinizing hormone-releasing hormone 
(LHRH) agonists or aromatase inhibitors (AIs) (Figure 1.2) (3, 22-24)
SERMs
SERMs are therapeutic agents functioning in a tissue-specific manner. They are agonists 
in some tissues, such as the endometrium and bone, and antagonists in others, like 
breast (25). The SERM tamoxifen has been the mainstay of endocrine therapy of breast 
Figure 1.1 
 
 
 
Figure 1.2 
 
 
 
Figure 1.2 Various classes of endocrine agents are used to treat ER positive breast cancer. In premenopausal women LHRH agonists desensitize 
the hypothalamus-pituitary-ovarian axis blocking the production of estrogens by the ovaries. In postmenopausal women aromatase inhibitors 
(AIs) prevent the conversion of androgens into estrogens in peripheral tissues. SERMs and SERDs prevent ER-mediated cell replication by binding 
to or degrading the ER.
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cancer for more than 25 years. It is able to bind the ligand-binding domain of the estro-
gen receptor, altering the molecular conformation of the receptor. Usually co-repressor 
instead of co-activator proteins are recruited, resulting in inhibition of transcription and 
subsequent tumor growth. Tamoxifen improves survival in patients with early breast 
cancer (26) and improves the quality of life when used as palliative treatment (27). Due 
to its agonistic activity, tamoxifen slightly preserves bone density. However, it is also as-
sociated with an increased risk of thromboembolic events (28) and endometrial cancer 
(29) in postmenopausal women. To reduce some of the harmful effects of tamoxifen 
other SERMs, like raloxifene, have been developed. Raloxifene has been shown to be 
equally effective as tamoxifen in reducing the risk of invasive breast cancer and has less 
side-effects. However, for treatment of premenopausal women the efficacy and safety of 
raloxifene have not been examined extensively enough yet (30).
Besides decreasing breast-cancer recurrence when used for adjuvant therapy, SERMs 
also play a role in breast-cancer prevention. Tamoxifen is the only drug approved for 
chemoprevention of breast cancer. In high-risk premenopausal and postmenopausal 
women it decreases breast-cancer incidence by 30-50% (29, 31-34). The main concern 
about using tamoxifen as a chemopreventive agent in postmenopausal women, are the 
side-effects (29, 34), an increased risk of thromboembolic events (28) and endometrial 
cancer (29). However, these side effects were less severe in premenopausal women (4, 
35), who therefore have a favorable risk-benefit ratio for using tamoxifen in chemopre-
vention.
SERDs
Upon ER binding SERDs, such as fulvestrant (Faslodex/ICI 182,780) (Astrazeneca), inhibit 
receptor dimerization and abrogate estrogen signaling. Fulvestrant may be beneficial in 
the treatment of ERα-expressing tamoxifen-resistant tumors (22, 36). It has no demon-
strable agonistic activity and therefore it does not increase blood-cloth and endometri-
al-cancer risk, nor preserves bone density (22). Fulvestrant is mainly applied as a therapy 
for postmenopausal women. Recent findings, however, suggest a possible benefit for 
premenopausal women as well (37). The value of fulvestrant for premenopausal women 
and its value in the adjuvant setting remain to be further established.
LHRH agonists
Traditionally, ovarian ablation had been accomplished irreversibly via irradiation or 
surgery, but luteinizing hormone-releasing hormone (LHRH) agonists have emerged as 
reliable and reversible agents for this purpose. LHRH agonists act by desensitization of 
the hypothalamus-pituitary-ovarian axis. It has been demonstrated, that combination 
treatment of an LHRH agonist with tamoxifen is superior to treatment with an LHRH 
agonist alone in premenopausal women with advanced breast cancer (38).
General introduction
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AIs
In postmenopausal women, estrogens are biosynthesized from circulating androgens 
by the enzyme aromatase. Aromatase inhibitors anastrozole, letrozole, and exemestane 
have shown to be superior to tamoxifen in the first-line treatment of advanced disease 
(39-41). Although less severe than tamoxifen, aromatase inhibitors also show side-
effects, including bone calcium loss (dependent on the type of AI) and musculoskeletal 
effects (42). As aromatase inhibitors are ineffective in premenopausal women with an 
intact hypothalamus-pituitary-ovarian axis, ovarian ablation and tamoxifen (combined 
with LHRH agonists or not), remain the only proven endocrine interventions for the 
treatment of these women.
mechanIsms of tamoxIfen-therapy faIlure
Although tamoxifen has proven to be effective in treatment of breast cancer for many 
years now, resistance remains a common feature that limits the success of this type of 
therapy. It is known that not all patients who have ERα-positive tumors respond to ta-
moxifen therapy (intrinsic resistance) and even in patients who are initially responsive, 
the disease ultimately progresses (acquired resistance). Several recent review articles 
have discussed the mechanisms of tamoxifen resistance (43-46) and those are briefly 
summarized here.
Pharmacologic mechanisms
A common mechanism of drug resistance is a decreased intracellular drug concentration 
due to an altered in- or efflux, often mediated by membrane pumps. Such a mechanism 
has also been suggested to be involved in tamoxifen resistance, although the precise 
cause remains unclear (45 and references therein).
In the body, tamoxifen can be metabolized to N-desmethyltamoxifen, and the active 
forms 4-hydroxy-tamoxifen and 4-hydroxy-N-desmethyltamoxifen (endoxifen). These 
metabolites have different affinities for the ER and different plasma concentrations 
and thus influence the efficacy of tamoxifen. Besides CYP3A4, the enzyme CYP2D6 is 
responsible for the conversion of the inactive metabolites to the active metabolites. It 
has been shown that genetic variability in CYP2D6 may affect treatment outcome in 
patients receiving tamoxifen therapy (47).
Altered ER expression or function
Since the effects of tamoxifen are primarily mediated through ERα, and this gene has a 
prominent role in predicting the response to tamoxifen therapy, loss of ERα could confer 
resistance. Indeed, lack of expression of ERα is the main mechanism of intrinsic resis-
14
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tance. However, it has been reported that patients with acquired resistance to tamoxifen 
usually do not lose expression of ERα. Loss has been demonstrated in 17-28% of these 
patients (48, 49). In fact, up to 20% of tamoxifen-resistant patients respond to second-
line therapy with aromatase inhibitors or fulvestrant suggesting that their tumors still 
express functional ERα (50, 51). Mutations in or specific variants of ERα might also effect 
the response to tamoxifen (52-54), but published studies have shown that these are 
rare in breast-cancer patients and are unlikely to contribute significantly to tamoxifen 
resistance (55, 56). In addition, no conclusions on whether altered expression of ERβ 
may play a role in tamoxifen resistance can be drawn at this point.
Alterations in co-regulatory proteins
The transcriptional regulatory activity of ER is mainly mediated by the formation of com-
plexes with co-activator or co-repressor proteins. Usually co-activators bind the ER when 
it is bound by estrogen, enhancing target gene transcription. When an antagonist such 
as tamoxifen is bound to ER, typically co-repressors are recruited which results in repres-
sion of target gene transcription. Under specific conditions, like high ERBB2 activity, a 
tamoxifen-ER complex may also recruit co-activator proteins, causing agonistic effects. 
Altered expression of co-regulators may therefore play a role in tamoxifen resistance 
(reviewed in 12, 57). It has been demonstrated in vitro that the co-activator proteins 
AIB1, PGC-1β, and SRC1 enhance the agonistic activity of tamoxifen (58, 59). In patients 
receiving adjuvant tamoxifen therapy, high levels of AIB1 alone or in combination with 
high levels of ERBB2 are associated with shorter disease-free survival in patients (60). 
These findings support a role for overexpression of co-activators in tamoxifen resistance. 
However, high levels of SRC1 were associated with favorable response to tamoxifen in 
patients (61), which does not fit with this hypothesis. The presence of other factors, like 
ERBB2, might play a role in this outcome (57). In addition, two studies showed that low 
levels of the co-repressor protein NCOR1 predict poor response to tamoxifen (62, 63). 
These results support the possibility that reductions in co-repressor activity may also 
contribute to tamoxifen resistance.
Modification of growth-factor signaling
Tamoxifen resistance may also be explained by altered expression and/or modification 
of several growth factor receptors and downstream signaling molecules. Resistant tu-
mors often show activation or elevated levels of tyrosine kinase receptors such as the 
insulin-like growth factor 1 receptor (IGF-1R), the epidermal growth factor receptor 
(EGFR), and ERBB2. Activity of molecules that function downstream of these receptors 
like mitogen-activated protein kinase 1 and 3 (MAPK1 and 3, also known as ERK2 and 
ERK1), MAPK 14 (p38), AKT, and p21-activated kinase-1 (Pak1) may also be associated 
with resistance (44, 64). It is suggested that these growth factor receptors and their 
General introduction
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as through independent pathways.
Despite tremendous advances in understanding growth factor-receptor and estrogen-
receptor signaling, underlying mechanisms for general tamoxifen-therapy failure still 
have to be elucidated. Although alternative treatment strategies using modern SERMs 
and AIs are very promising, these therapies eventually fail as well. Thus it remains im-
portant to gain insights into the mechanisms underlying endocrine-therapy failure, be-
cause it will help us to develop new therapeutic strategies and to overcome endocrine 
resistance in breast-cancer patients.
experImental strategIes to unravel tamoxIfen-therapy resIstance
Non-functional profiling strategies
High-throughput molecular technologies provide insight into the DNA, RNA, and 
protein levels of complex biological samples. RNA expression profiling techniques, al-
lowing simultaneous analysis of up to tens of thousands of genes, include PCR-based 
differential display (65), sequencing based serial analysis of gene expression (SAGE) 
(66), and hybridization-based DNA microarrays. In the last decades, various studies have 
been performed for identifying biological factors that predict the success of tamoxifen 
treatment (67). Paik et al. performed a reverse-transcriptase polymerase chain reac-
tion (RT-PCR) assay on 250 prospectively selected genes generating a 21-gene profile 
that predicts the recurrence of tamoxifen-treated, node-negative breast cancer (68). 
Furthermore, two studies using microarray technology for generating a gene signature 
predictive for response to tamoxifen have been reported (69, 70). Ma and colleagues de-
veloped a two-gene signature, HOXB13/IL17BR, predictive for disease-free survival from 
60 patients treated with adjuvant tamoxifen. From 46 tumors, Jansen et al. identified 81 
genes that predicted for response to the therapy. However, a gene signature classifier 
that is good at prediction may not necessarily contain the genes that are functionally 
responsible for resistance. Functional proof has to be provided through transfection or 
functional knockdown using siRNAs.
Functional profiling strategies
For identifying genes causing tamoxifen resistance, several functional genetic screens 
were applied, namely transfection of candidate genes, cDNA library transfection, retro-
virus insertion mutagenesis, and retroviral transduction of cDNA libraries. Transfection 
of candidate genes included the selection of several candidate genes from array data. 
Subsequently, the genes were introduced into estrogen-dependent breast-cancer cells 
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and tested for their altered hormone dependency (71). Toi et al. randomly searched for 
genes involved in tamoxifen resistance by transfecting cDNA libraries into tamoxifen-
sensitive MCF-7 cells, though with limited success. One tamoxifen-resistant cell line was 
isolated, but involvement of the integrated cDNA was never established (72).
Retrovirus insertion mutagenesis and retroviral transduction of cDNA libraries were 
more successful approaches for finding genes causing tamoxifen resistance. In retrovi-
rus-mediated insertion mutagenesis retroviruses randomly integrate into the genome 
of target breast cancer cells as part of their life cycle (73). As a result, they cause single 
genetic modifications which may enhance or disturb local gene expression, leading 
to an altered and selectable phenotype (Figure 1.3). Furthermore, the integrated viral 
Figure 1.3  
 
Figure 1.3 Retrovirus insertion mutagenesis and retroviral transduction of cDNA libraries have shown to be successful techniques for identifying 
genes responsible for tamoxifen resistance in vitro. In the first, retroviruses randomly integrate into the genome of target ZR-75-1 breast cancer 
cells as part of their life cycle. This results in alteration of local gene expression which may facilitate cell proliferation in the presence of tamoxifen. 
In the latter, packaging cells are transfected with cDNA libraries, resulting in production of replication-defective virus containing cDNA inserts. 
Subsequent infection of target cells causes cDNA overexpression in the cells and may facilitate cell proliferation in the presence of tamoxifen.
General introduction
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tion mutagenesis in ZR-75-1 human breast cancer cells, revealed twelve common viral 
integration sites (cVISs) promoting tamoxifen-resistant cell proliferation (74-77 and 
manuscript in preparation).
Of Breast Cancer Antiestrogen Resistance (BCAR) genes 1 (p130Cas) and 3, two genes 
located within two cVIS loci, overexpression was shown to confer tamoxifen resistance. 
The molecular mechanism by which elevated expression of BCAR1 promotes prolif-
eration still has to be elucidated. It is known to be independent from the ER and EGFR 
pathways (78) and may be involved in enhancing downstream signaling. BCAR3 induces 
tamoxifen resistance by enhancing PI3K-mediated Rac1 activation (79). Furthermore, 
BCAR3 associates with BCAR1 and increases cell migration, suggesting that BCAR3-
mediated tamoxifen resistance is the result of altered adhesion-related signaling (80). 
In breast cancer patients, high levels of BCAR1 are associated with poor prognosis and 
predict a poor response to tamoxifen treatment in case of recurrent disease (81-84).
Although insertion mutagenesis was shown to be successful, the identification of the 
genes responsible for the tamoxifen-resistant phenotype appeared to be very labor-
intensive. To overcome this technical limitation, a more rapid screening technique 
using retroviral transduction of cDNA libraries was used. With this technique, cells are 
infected with replication-defective retroviruses containing cDNAs (or siRNAs) derived 
from various tissues (Figure 1.3). Genes responsible for an altered selectable phenotype 
can easily be identified by PCR using virus-specific primers (85). Several genes that may 
be key players in the tamoxifen resistance of human breast cancer cells were identified 
using this approach (86). Recently, functional screens using RNAi have also resulted in 
the identification of genes involved in resistance to tamoxifen (87) and other treatment 
modalities (88-90).
aIms and outlIne of the thesIs
Although women with breast cancer have successfully been treated with tamoxifen dur-
ing the past decades, resistance to this therapy remains an important issue. It is known 
that many different molecular mechanisms may account for tamoxifen resistance and 
identification of the genes involved may help improving diagnostics and individualizing 
breast-cancer treatment. The aim of this thesis is identifying genes involved in tamox-
ifen resistance. In chapter 2 a rapid screening strategy is described, revealing several 
causative genes. In chapter 3 the predictive value of FGF17, one of the causative genes, 
and the receptors FGFR1, 2, 3 and 4 were assessed for the type of response to tamoxifen 
treatment and the duration of progression-free survival in patients with recurrent breast 
cancer. Combination of the results of a microarray study for generating a gene signature 
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predictive for response to tamoxifen treatment and the results of a functional screen 
for causative genes described in chapter 2, revealed two overlapping genes, TSC22D1 
and PSAP. The association of these genes with the duration of progression-free survival 
in patients with recurrent breast cancer is described in chapter 4. Chapter 5 describes 
further characterization of BCAR4, a novel gene involved in tamoxifen resistance as was 
reported in chapter 2. Chapter 6 summarizes the major findings of the studies described 
in this thesis and discusses the future perspectives.
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abstract
Antiestrogens, such as tamoxifen, are widely used for endocrine treatment of estrogen 
receptor-positive breast cancer. However, as breast cancer progresses, development of 
tamoxifen resistance is inevitable. The mechanisms underlying this resistance are not 
well understood. To identify genes involved in tamoxifen resistance, we have devel-
oped a rapid screening method. To alter the tamoxifen-sensitive phenotype of human 
ZR-75-1 breast cancer cells into a tamoxifen-resistant phenotype, the cells were infected 
with retroviral cDNA libraries derived from human placenta, human brain, and mouse 
embryo. Subsequently, the cells were selected for proliferation in the presence of 4-hy-
droxy-tamoxifen (OH-TAM) and integrated cDNAs were identified by sequence similarity 
searches. From 155 OH-TAM-resistant cell colonies, a total of 25 candidate genes were 
isolated. Seven of these genes were identified in multiple cell colonies and thus cause 
antiestrogen resistance. The epidermal growth factor receptor, platelet-derived growth 
factor receptor-α, platelet-derived growth factor receptor-β, colony-stimulating factor 1 
receptor, neuregulin 1, and fibroblast growth factor 17 that we have identified, have been 
described as key regulators in the mitogen-activated protein kinase pathway. Therefore, 
this pathway could be a valuable target in the treatment of patients with breast cancer 
resistant to endocrine treatment. In addition, the putative gene LOC400500, predicted 
by in silico analysis, was identified. We showed that ectopic expression of this gene, des-
ignated as breast cancer antiestrogen resistance 4 (BCAR4), caused OH-TAM resistance 
and anchorage-independent cell growth in ZR-75-1 cells and that the intact open read-
ing frame was required for its function. We conclude that retroviral transfer of cDNA 
libraries into human breast cancer cells is an efficient method for identifying genes 
involved in tamoxifen resistance.
Functional screen for tamoxifen resistance
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IntroductIon
Tamoxifen is the most extensively used antiestrogen in the treatment of breast cancer. 
Patients with estrogen receptor (ER)-positive breast tumors may initially benefit from 
this treatment, but almost all responding patients acquire resistance to the action of ta-
moxifen over time and the disease progresses. Several mechanisms for this phenomenon 
have been suggested, including alteration of the availability or metabolism of tamox-
ifen, alterations in the function of the ER and in the ER signaling cascade, and the altered 
expression of different genes (reviewed by 1, 2). However, in the majority of patients, the 
mechanisms causing tamoxifen-resistant proliferation remain unexplained. Insight into 
these processes is essential for the development of improved treatment strategies and 
may be obtained by the application of genome-wide functional screens.
Random transfection of cDNA libraries was previously used to identify the specific 
genes involved in progression to antiestrogen resistance of human breast cancer cells, 
but this had only limited success (3). On the other hand, our group has successfully 
identified such genes using retroviral insertion mutagenesis in functional screens (4). 
Although insertion mutagenesis has shown itself to be a very powerful tool in the identi-
fication of genes involved in mouse tumorigenesis, in our experiments the identification 
of the genes responsible for antiestrogen-resistant proliferation has proved to be very 
labor intensive (5-7).
To bypass this technical limitation, we have developed a rapid screening strategy 
for identifying genes that cause tamoxifen-resistant cell proliferation. In this study, we 
used replication-defective retroviruses to express cDNAs, a strategy that has previously 
been used for various experimental purposes (8-10). We applied this methodology to 
estrogen-dependent human ZR-75-1 breast cancer cells and here report the identifica-
tion of several genes that may be key players in the resistance of human breast cancer 
cells to antiestrogenic drugs.
results
Functional screens for tamoxifen resistance
ZR-75-1 human breast cancer cells were infected with retroviral cDNA libraries derived 
from either human placenta, human brain, or mouse embryo (Figure 2.1). After infec-
tion, the cells were selected for growth in the presence of 4-hydroxy-tamoxifen (OH-
TAM). The first resistant colonies were observed 3 weeks after retroviral transduction, 
and all colonies were picked within 6 weeks after start of the experiments. Three inde-
pendent cell cultures (a total of 1.2 x 107 cells) were infected with the human placenta 
cDNA library, and 80 tamoxifen-resistant cell colonies were isolated. In addition, 30 cell 
28
Chapter 2
colonies were isolated from three flasks with independent cell cultures (107 cells each) 
infected with the mouse embryo cDNA library. To prevent the isolation of many identi-
cal cell colonies due to reseeding of proliferating cells, 32 individual 25cm2 flasks with 
approximately 106 cells each (a total of 3.2 x 107 cells) were infected with viral particles 
derived from a human brain library. In total, 45 cell colonies were isolated from the cell 
cultures infected with this library. In control experiments, ZR-75-1 cells mock infected 
or infected with pLIB-EGFP virus failed to produce proliferating colonies in the presence 
of OH-TAM within 6 weeks. In total, 7.4 x 107 cells were transduced with viral particles 
of three different cDNA libraries, resulting in 155 resistant cell colonies. The estimated 
infection frequency was approximately 10%; thus, the frequency of cell colonies was at 
least a 2,000-fold higher than that of spontaneous antiestrogen-resistant cell colonies in 
control cultures (below 10-8) (4).
Figure 2.1 
cDNA library no of cells no of colonies
human placenta 
human brain 
mouse embryo 
 
1.2 x 107 
 
3 x 107 
 
3.2 x 107 
total 
 
7.4 x 107 
80 
30 
45 
155 73 
Criterion 1: single PCR product 
7 genes causing tamoxifen 
resistance  
no of cDNAs
11
31 
31 
25 candidate genes (Table 1) 
Criterion 2: two independent cell colonies
Figure 2.1 Study outline: Functional screen for tamoxifen resistance.
ZR-75-1 cells were transduced with retroviral cDNA libraries derived from human placenta (3 independently infected cell cultures), mouse embryo 
(3 independently infected cell cultures) and human brain (32 independently infected cell cultures). A total of 73 different genes were identified. In 
25 colonies only one integrated cDNA was observed, suggesting a causative role in tamoxifen resistance for the genes identified (Table 1). Seven of 
these genes were isolated from at least two independently derived cell colonies, complying with our second criterion.
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Genes recovered from screens for tamoxifen resistance
Genomic DNA was isolated from resistant cell colonies, and integrated cDNAs were recov-
ered using PCR assays. These assays showed that the majority of the tamoxifen-resistant 
cell colonies contained only one retroviral insert (range 1-6; median 1). Approximately 
one third of the isolated colonies contained multiple retroviral integrations.
In one of the OH-TAM-resistant cell lines obtained after infection with the placenta 
cDNA library, PCR analysis failed to detect an integrated cDNA. Southern blot analysis 
showed that this particular cell line contained an integrated retrovirus with only one 
retroviral long terminal repeat, likely the result of a truncation event during integration 
of the retrovirus in the host genome. The integrated cDNA in this cell line was success-
fully isolated using an inverse DNA amplification technique (11, 12). This phenomenon 
indicates that not every integrated cDNA may be detected by PCR analysis using primers 
located adjacent to the inserted cDNAs. Therefore, truncated retroviruses may lead to 
misconceived conclusions for some of the genes identified in a screen. In addition, we 
have shown previously that tamoxifen-resistant cell colonies may result from insertion 
mutagenesis of a retrovirus independent of its cDNA insert at a frequency of one colony 
per approximately 2 million cells (4). To ascertain that an inserted cDNA was actually re-
sponsible for tamoxifen resistance and to exclude wrong assignments as a consequence 
of virus truncation or insertion mutagenesis events, we applied the following criteria. 
First, each candidate cDNA represented a single product following 35 cycles of PCR with 
genomic DNA from at least one tamoxifen-resistant cell colony. Second, a particular 
cDNA should be recovered from at least two independently derived cell colonies. This 
independence was established by differences in length of the 5’-noncoding region of 
the inserted cDNAs or if cell colonies originated from infections of independent cell 
cultures. Analyses of the cDNAs isolated from the resistant colonies revealed a total of 
73 different genes (Figure 2.1). Twenty-five genes (listed in Table 2.1) complied with the 
first criterion and are considered candidate genes. Seven of these genes also complied 
with the second criterion and thus caused tamoxifen resistance in ZR-75-1 cells. We fully 
sequenced the cDNA inserts of two independent colonies of each of these seven genes 
and confirmed the presence of cDNAs containing the complete open reading frame 
lacking mutations.
Among the seven genes causing tamoxifen resistance, four different receptor tyrosine 
kinases (RTK) were present: epidermal growth factor receptor (EGFR), colony-stimulat-
ing factor 1 receptor (CSF1R), mouse platelet-derived growth factor (PDGF) receptor-α 
(Pdgfra), and both mouse and human PDGF receptor-β (Pdgfrb and PDGFRB). Four cell 
colonies with integrated EGFR cDNAs were isolated from one cell culture infected with 
the human placenta library, as were two CSF1R cDNAs. Lenght differences at the 5’-end 
detected by sequence analysis confirmed their independent origin. Six of seven Pdgfra 
cDNAs were recovered from two independent cell cultures infected with the mouse 
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embryo library. PDGFRB was identified in 12 colonies retrieved from one cell culture 
infected with the placenta library. At least two cell colonies had an independent ori-
gin, because the inserted cDNAs differed at the 5’-end. Seventeen Pdgfrb cDNAs were 
Table 2.1 Summary of the genes identified in the screen*
Gene NCBI UniGene No of total 
isolates†
No of independent 
isolates‡
Library# Function§
LOC400500 Hs.24611 52 26 hp unknown
Pdgfrb Mm.4146 17 14 me RTK||
PDGFRB Hs.509067 12 2 hp RTK
FGF17 Hs.248192 12 8 hb ligand of RTK
NRG1** Hs.453951 8 6 hb ligand of RTK
Nrg1** Mm.153432 4 2 me ligand of RTK
Pdgfra Mm.221403 7 6 me RTK
EGFR Hs.488293 4 2 hp RTK
CSF1R Hs.483829 2 2 hp RTK
Psap Mm.277498 2 1 me enzyme activator
ASMTL Hs.533514 2 1 hp unknown
ALK Hs.196534 2 1 hb RTK
APLP1 Hs.74565 1 1 hb protein binding
APP Hs.434980 1 1 hb signaling
CBFA2T3 Hs.513811 1 1 hb transcription
ERBB2 Hs.446352 1 1 hp RTK
GFAP Hs.514227 1 1 hb Intermediate fillament
GFI1B Hs.118539 1 1 hp zinc finger protein
NEDD9 Hs.37982 1 1 hp signaling
HRAS Hs.37003 1 1 hp signaling
KIAA0513 Hs.301658 1 1 hb unknown
L1CAM Hs.522818 1 1 hb cell adhesion
CLDN23 Hs.183617 1 1 hp cell adhesion
MDC1 Hs.433653 1 1 hb DNA repair
PB1 Hs.189920 1 1 hb DNA binding
PTMA Hs.459927 1 1 hp transcription
STX1A Hs.488683 1 1 hb protein binding
* Inserted cDNAs were listed when they were the only product after 35 PCR cycles in the analysis of at least one cell colony. Seven of these cDNAs 
were found at least twice as independent event.
† Number of cell colonies identified with the respective gene.
‡ Number of independent cDNAs found using a particular cDNA library.
# hp: human-placenta library, hb: human-brain library, me: mouse-embryo library.
§ Function was derived from the NCBI/Gene database.
|| RTK: receptor tyrosine kinase.
** only transcript variant SMDF was identified.
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isolated from resistant colonies retrieved from cell cultures infected with the mouse 
embryo library. Fourteen of these differed at the 5’-end, or were recovered from autono-
mous cell cultures and have thus arisen independently. In addition to the RTK genes, 
we identified mouse and human neuregulin1 (Nrg1 and NRG1) and human fibroblast 
growth factor (FGF) 17. The Nrg1 gene was isolated four times from two independent 
cell cultures infected with the mouse embryo library, and the human NRG1 was isolated 
eight times from six cell cultures independently infected with the brain library. All cell 
colonies contained the NRG1 sensory and motor neuron-derived factor isoform (SMDF). 
FGF17 was identified in 12 colonies isolated from eight independent cell cultures in-
fected with the human brain library.
LOC400500 (assigned as breast cancer antiestrogen resistance 4 (BCAR4), see discus-
sion), a putative gene predicted by in silico analysis of the human genome (Hs.24611, 
accession no. XM_378564), was the cDNA most frequently found. Based on sequence 
and Southern blotting analysis of PCR products, we recovered LOC400500 52 times 
only in the different cell cultures infected with the human placenta library. At least 26 
of these cDNAs were proven to be of independent origin. Sequence similarity analyses 
showed that the cDNAs had variable 5’-ends. However, all cDNAs contained an open 
reading frame encoding a 121-amino acid polypeptide identical to the open reading 
frame predicted for LOC400500 gene.
Ectopic Expression of LOC400500/BCAR4 Induces Antiestrogen Resistance and 
Anchorage-Independent Transformation
Additional experiments were done to confirm that the putative gene LOC400500 is able 
to induce tamoxifen-resistant proliferation in human ZR-75-1 breast cancer cells. ZR-75-1 
cells were infected with retroviruses containing either an LZRS-IRES-Neo/LOC400500 
expression construct or the LZRS-IRES-Neo expression vector without insert, designated 
as ZR/BCAR4 and ZR/LZRS, respectively. After infection, cells were selected with G418 in 
17β-estradiol (E2)-containing medium. Proliferation of the different cell pools, originating 
from approximately 105 colonies each, was similar in the presence of E2-supplemented 
medium (Figure 2.2A). We next determined the capacity of the transduced cells to prolif-
erate in the presence of OH-TAM. In Figure 2.2B proliferation curves over a 21-day culture 
period of these cells are presented. These curves show the dominant role of LOC400500/
BCAR4 in tamoxifen-resistant proliferation of ZR-75-1 cells.
To establish whether the protein predicted for LOC400500/BCAR4 is responsible for 
tamoxifen resistance, a frameshift mutation was introduced using site-directed muta-
genesis. This resulted in the addition of 20 heterologous amino acids after amino acid 
position 5 before reaching a stop codon. ZR-75-1 cell cultures were infected in duplicate 
with virus containing this frameshift construct (ZR/BCAR4-fs). Parallel infections were 
done with BCAR4 or LZRS virus to generate control cultures (ZR/BCAR4 and ZR/LZRS, 
32
Chapter 2
respectively). Two days after infection, 5% of the cells were plated in medium containing 
OH-TAM. In the ZR/BCAR4 cultures, proliferating cell colonies (average of 4,100 per flask) 
were observed within 3 weeks, whereas no proliferating cell colonies could be detected 
in ZR/BCAR4-fs cultures and in ZR/LZRS control cultures up to 5 weeks. Another 5% of 
the cells were plated in medium containing E2 plus G418, and successful infection was 
shown by the presence of G418-resistant colonies in ZR/BCAR4, ZR/BCAR4-fs, and ZR/
LZRS cell cultures (average of 5,000, 3,950, and 4,150 colonies per flask, respectively). 
These data argue for a direct role of the protein instead of the RNA.
A soft agar assay was used to determine anchorage-independent transformation of ZR/
BCAR4 cells in vitro. Parental ZR-75-1 cells are only capable of anchorage-independent 
proliferation in the presence of estradiol. In the absence of estradiol colony formation is 
almost fully abrogated. ZR-75-1 vector control and ZR/BCAR4 cells (1 x 105) were plated 
in bovine calf serum-supplemented soft agar in duplicate. In ZR-BCAR4 cell cultures, 
colonies appeared within 10 days and were counted after 5 weeks. Large numbers of 
colonies were observed for ZR/BCAR4 cells (16,800 per 1 x 105) compared with ZR-75-1 
vector control cells (45 per 1x 105; Figure 2.3).
dIscussIon
In this study, we identified seven genes involved in antiestrogen-resistant prolifera-
tion. Our breast cancer cell model for antiestrogen resistance has proven to be almost 
background-free, allowing the identification of genes involved in tamoxifen resistance 
Figure 2.2 LOC400500/BCAR4 induces antiestrogen resistant proliferation.
Independent pools of ZR-75-1 cells, infected with virus from the expression vector without cDNA insert (ZR/LZRS) or containing LOC400500/
BCAR4 (ZR/BCAR4), were plated in medium containing E2 or OH-TAM in triplicate. At the timepoints indicated, the cells were counted and replated 
at the initial density. Cumulative cell numbers ± 95% confidence interval are presented over a 21 day culture period. (A) proliferation curves of 
the cells in medium containing E2. (B) proliferation curves of the cells in duplicate in medium containing OH-TAM.
Figure 2.2 
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using insertion mutagenesis (4). Random insertion of retroviruses in the cellular ge-
nome causes local disturbance of the genome structure (13) and may affect expression 
of adjacent genes (14, 15). Infection of ZR- 75-1 cells resulted in the identification of 
seven BCAR genes and an additional seven common viral integration sites (5-7, and 
in preparation). The frequency of retrovirally induced antiestrogen-resistant colonies 
was approximately 5 x 10-7 (4), and the probability of activating one of the BCAR genes 
most frequently found in our study was at least 10-fold lower. Our current experiments 
with retroviral transduction of cDNA libraries derived from human placenta, human 
brain, and mouse embryo proved to be 40 times more efficient in inducing tamoxifen 
resistance than insertion mutagenesis. Furthermore, identifying the genes responsible 
was less time consuming. On the other hand, the nature of the cDNAs identified in the 
screens is strongly dependent on the cDNA library used, whereas insertion mutagenesis 
is an almost random process. The contribution of insertion mutagenesis events in this 
study can be ignored in view of its very low frequency (5 x 10-7) and the application 
of our stringent selection criteria, as detailed in the study outline and Table 1. Hence, 
this strategy obviates the need for a second round of selection involving replication-
competent amphotropic viruses or time-consuming construction of suitable expression 
vectors.
Of the 73 genes identified in our current screens, 7 fulfilled both selection criteria and 
are thus considered to be responsible for antiestrogen resistance. Two of these genes 
(EGFR and LOC400500/BCAR4) have been confirmed to cause tamoxifen resistance in 
ZR-75-1 cells by gene transfer experiments (16, and this article). Four of these genes are 
expressed at extremely low levels (EGFR) or are undetectable (PDGFRA, PDGFRB, and 
LOC400500/BCAR4) in the parental ZR-75-1 cells (17, and unpublished results). Thus, the 
infected cells acquired a novel function essential for tamoxifen-resistant proliferation. 
Figure 2.3 LOC400500/BCAR4 induces anchorage-independent transformation.
A total of 1 x 105 ZR-75-1 vector control cells (ZR/LZRS) and 1 x 105 ZR-75-1 cells containing LOC400500/BCAR4 (ZR/BCAR4) were plated in BCS-
supplemented soft agar in duplicate. Representative light-microscopy photographs of flasks with ZR/LZRS (A) or ZR/BCAR4 (B) cells after five 
weeks are shown.
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Eighteen of the 73 genes complied only with the first criterion (Figure 2.1; Table 2.1) 
and are considered to be interesting candidates. Formal prove of their role in tamoxifen 
resistance may be obtained in additional cDNA library transduction experiments or by 
individual gene transfer experiments.
The majority of the genes identified in this study are involved in RTK signaling. We 
identified four full length RTKs: mouse Pdgfra, both human and mouse PDGFRB, human 
CSF1R and human EGFR, which have previously been classified into two subfamilies on 
the basis of common structural features (18).
PDGFRA, PDGFRB and CSF1R are members of the PDGFR RTK subfamily, which also 
encompasses KIT and the FGF receptors. Previous studies have shown the presence of 
PDGFRB mRNA in breast cancer cells (19). Aberrant expression of CSF1R has also been 
documented in a variety of malignancies, including breast cancer (reviewed by 20). In 
mice bearing human breast cancer xenografts and treated with small interfering RNAs 
directed specifically against the CSF1R mRNA, tumor growth was suppressed by 40 to 
50% and mouse survival increased (21).
EGFR is part of an RTK subfamily, including ERBB2, which is also among our list of 
candidate genes (Table 2.1), and ERBB3, and ERBB4. EGFR has been reported previously 
to play an important role in normal development, differentiation, and cell prolifera-
tion (reviewed by 22). High levels of EGFR promote antiestrogen-resistant proliferation 
in breast cancer cells and are associated with failure of tamoxifen treatment (16, 23). 
However, because expression of EGFR is inversely related to expression of ERα in breast 
cancers (24, 25), it is unlikely that EGFR plays a dominant role in antiestrogen resistance 
in ER-positive breast cancers.
We also identified the EGF-like ligand NRG1, which interacts with ERBB3 and ERBB4 
receptors, leading to formation of ERBB homodimers or heterodimers (often including 
ERBB2). In our screens using both a human brain and a mouse embryo cDNA library 
we identified the NRG1 sensory and motor neuron-derived factor isoform, which shares 
only the EGF-like domain with other NRG1 isoforms (26). High expression levels of NRG1 
have been shown to cause progression of MCF-7 breast cancer cells to an estrogen-
independent and antiestrogen-resistant state, which was later mimicked in a transgenic 
mice model (27).
FGF17, a ligand for the FGF receptor subfamily, was identified as well. Among known 
FGF family members, the FGF17 protein is most similar to FGF8 (28). Together with FGF8 
and FGF18, it forms a subfamily, having similar gene structures, overlapping patterns of 
expression, and receptor-binding specificities (29). Overexpression of FGF8 and FGF17 
in NIH-3T3 cells results in a transforming and tumorigenic phenotype (30, 31). Further-
more, FGF8 expression is significantly higher in breast cancer and in prostate cancer 
than in nonmalignant tissues (32, 33). Although no data are available for FGF17 expres-
sion in breast cancer yet, Heer et al. (34) reported a significant increase in FGF17 mRNA 
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expression in high-grade prostate cancers compared with benign prostatic hyper trophic 
tissues.
In addition to these known genes, we identified LOC400500, a putative gene positioned 
at human chromosome 16p13.1. It was recovered from 65% of the tamoxifen-resistant 
cell colonies obtained after transduction with a human placenta cDNA library. The gene 
has been designated as BCAR4. Sequence similarity analyses showed that all BCAR4 
cDNAs contained the same open reading frame of 121 amino acids. The amino acid 
sequence shows no homology with other proteins yet nor typical conserved domains. 
The presence of a putative signal peptide sequence (www.ebi.ac.uk/InterProScan/) sug-
gests that BCAR4 is transported to the membrane. The presence of two putative trans-
membrane regions further supports this hypothesis. The only homologues of BCAR4 
reported until now were found in chimpanzee (100% identical) and rhesus monkey 
(92% identical). Thus, this gene may have emerged during the primate evolution. Here, 
we showed that this novel identified gene causes antiestrogen resistance in ZR-75-1 
cells. Furthermore, loss of antiestrogen resistance due to a frameshift mutation strongly 
suggests that expression of the small protein is responsible for this resistance. We also 
showed anchorage-independent transformation of BCAR4 cells in a soft agar assay. 
From serial analysis of gene expression data (http//bioinfo.amc.uva.nl/HTMseq/) and 
EST profiles (www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Hs.24611), it 
is clear that BCAR4 is expressed in placenta and embryo. In addition, analysis of our 
expression data (35) and published array data (36, 37) indicates that BCAR4 expression is 
present in approx imately 10% of breast cancers.
In our future studies, we will establish which genes identified in vitro are important 
in progression of breast cancer in patients. We have already documented that genes 
identified in a screen for tamoxifen resistance can have clinical relevance (38, 39). The 
results from our planned studies will enable us to select particular genes for further 
study and to identify key regulators susceptible to targeted therapy.
In conclusion, retroviral transfer of cDNA libraries to human breast cancer cells is an 
efficient method for identifying genes involved in antiestrogen resistance in vitro. Six 
of seven genes that were identified in multiple resistant cell colonies are part of the 
mitogen-activated protein kinase pathway. This suggests that mitogen-activated pro-
tein kinase signaling may play an important role in tamoxifen resistance in human breast 
cancer. With the recent development of new tyrosine kinase inhibitors and antireceptor 
monoclonal antibodies, other genes involved in RTK signaling besides EGFR and ERBB2 
may represent valuable targets for therapy of tamoxifen-resistant breast cancer (40).
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materIals and methods
Cell lines and culture conditions
ZR-75-1 cells (41) were cultured in RPMI 1640 (Invitrogen, Paisley, United Kingdom) 
supplemented with 10% heat-inactivated bovine calf serum (standard medium; Hy-
clone, Logan, UT) and supplemented with 1 nmol/L E2 (Sigma-Aldrich, St. Louis, MO) as 
described previously (16).
Cell colonies resistant to OH-TAM (Sigma-Aldrich) were picked and expanded in RPMI 
1640 supplemented with 10% bovine calf serum and 10% conditioned medium of CRIP 
cells (mouse fibroblast cell line) and 1 µmol/L OH-TAM (4).
Transduction of retroviral cDNA libraries into ZR-75-1 cells
Retroviral transduction experiments were done using retroviral cDNA expression librar-
ies derived from human placenta, human brain, and mouse embryo (Clontech, Palo Alto, 
CA). Retroviral particles were produced by transient transfection of Phoenix-Ampho 
packaging cells (42) using FuGENE 6 (Roche Diagnostics GmbH, Mannheim, Germany) 
according to the manufacturer’s instructions. Cell-free supernatants containing viral 
particles were harvested after 2 and 3 days and stored at -80ºC. In total, 38 flasks with 
ZR-75-1 cells were incubated with pLIB-cDNA virus in the presence of 4 µg/mL polybrene 
(Sigma-Aldrich) and 1 nmol/L E2 to stimulate proliferation and integration of the retrovi-
ruses. To determine the infection frequency with fluorescence-activated cell sorting or 
fluorescence microscope analysis, cells were infected with a mixture of viral supernatant 
containing pLIB-EGFP (Clontech) together with viral supernatant of the placenta cDNA 
library. Alternatively, 1% of pLIB-EGFP construct was mixed with the library cDNA plas-
mids before production of the viral particles. Three days after infection, the cells were 
trypsinized and resuspended. The cells were plated in 75 cm2 flasks (4 x106 per flask) 
in medium containing 1 µmol/L OH-TAM. Within 6 weeks of plating, OH-TAM-resistant 
colonies were picked and transferred to 96-well or 48-well plates. Subsequently, the 
colonies were expanded for further characterization. Genomic DNA was isolated using 
NaCl extraction procedures as described by Miller et al. (43).
Analysis of proviral cDNA inserts
Integrated cDNAs were retrieved from genomic DNA by PCR using primers located in 
pLIB adjacent to the cDNA cloning site (44). PCR was done using the Expand High Fidel-
ity PCR System (Roche) and the Expand Long Template PCR System (Roche) according 
to the manufacturer’s instructions. PCR products containing multiple fragments were 
separated on and purified from 0.7% agarose gels using QIAquick gel extraction kits 
(Qiagen, Hilden, Germany). Sequence analysis was done on a LI-COR sequencer (LI-COR 
Inc., Lincoln, NE) using Thermo Sequenase DYEnamic direct cycle sequencing kits (Am-
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ersham plc, Buckinghamshire, United Kiongdom) or on an ABI Prism 3100 Genetic Ana-
lyzer (Applied Biosystems, Foster City, CA) using ABI Prism BigDye Terminators v3.0 cycle 
sequencing kits (Applied Biosystems) according to the protocols of the manufacturers. 
The cDNAs were identified by sequence similarity searches using Basic Local Alignment 
Search Tools (www.ncbi.nlm.nih.gov/BLAST/).
Expression constructs and proliferation assays
A cDNA, containing the predicted coding region of LOC400500, isolated from one of 
the resistant cell lines, was cloned into the LZRS-IRES-Neo expression vector (45) of 
which viral particles were produced. ZR-75-1 cells were infected in duplicate with ret-
roviral particles containing either the LOC400500 expression construct (ZR/BCAR4) or 
the LZRS-IRES-Neo expression vector without insert (ZR/LZRS). The cells were cultured 
in E2-containing medium, and after 2 days, selection with G418 (Invitrogen) was started. 
G418-resistant cell colonies were pooled and expanded. Pools of ZR/BCAR4 and ZR/
LZRS cells were harvested by trypsinization and counted with a Coulter Z1 cell counter 
(Coulter Electronics Ltd, Luton, United Kingdom). Subsequently, 3.5 x 105 cells were plat-
ed in triplicate in 25 cm2 tissue culture flasks. Experimental medium containing 1 nmol/L 
E2 or 1µmol/L OH-TAM was changed twice weekly. Cells were trypsinized, counted, and 
replated in fresh medium at the initial density once weekly.
A frameshift construct of LOC400500 was produced by inserting a thymine directly 
following the codon for amino acid 4. We did this site-specific mutagenesis with mu-
tated PCR primers, and the resulting construct was sequence verified. ZR-75-1 cells were 
infected in duplicate with retroviruses containing the frame-shift construct (BCAR4-fs). 
ZR/BCAR4 and ZR/LZRS cells were used as control cultures. The cells were cultured in 
E2-containing medium and trypsinized and resuspended after 2 days. Five percent of the 
cells were plated in medium containing 1 µmol/L OH-TAM. Colonies of proliferating cells 
were counted after 15 days. To establish whether the infection was successful, another 
5% of the cells were plated in 25 cm2 flasks in E2-containing medium. After 2 days, G418 
selection was started and colonies of proliferating cells were counted 6 days after start 
of selection.
To determine in vitro anchorage-independent transformation of ZR/BCAR4 cells, a soft 
agar assay was done. ZR/LZRS and ZR/BCAR4 cells (1 x 105) were plated in duplicate in 
0.3% soft agar with 10% bovine calf serum in RPMI1640 culture medium on 0.6% base 
agar layers containing the same ingredients. Colonies were counted after 5 weeks.
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abstract
Tamoxifen treatment of estrogen-dependent breast cancer ultimately loses its effective-
ness due to the development of resistance. From a functional screen for identifying genes 
responsible for tamoxifen resistance in human ZR-75-1 breast cancer cells, fibroblast 
growth factor (FGF) 17 was recovered. The aim of this exploratory study was to assess 
the predictive value of FGF17 and the receptors FGFR1-4 for the type of response to 
tamoxifen treatment (clinical benefit) and the duration of progression free survival (PFS) 
in patients with recurrent breast cancer. Messenger RNA levels of FGF17 and FGFR1-4 
were quantified by real-time reverse transcriptase PCR in 285 estrogen receptor-positive 
breast carcinomas with clinical follow-up. All patients had recurrent disease and were 
treated with tamoxifen as first-line systemic therapy for local or distant relapse. FGF17 
and FGFR1-3 mRNA levels had no significant predictive value for this group of patients. 
However, high FGFR4 mRNA levels analyzed as a continuous log-transformed variable 
predicted poor clinical benefit (odds ratio = 1.22; P = 0.009) and shorter PFS (hazard ratio 
= 1.18; P < 0.001). In addition, in multivariable analysis, the predictive value of FGFR4 was 
independent from the traditional predictive factors. Our analyses show that FGFR4 may 
play a role in the biological response of the tumor to tamoxifen treatment. In addition, 
as altered expression of FGF17 causes tamoxifen resistance in vitro, the FGF-signaling 
pathway could be a valuable target in the treatment of breast cancer patients resistant 
to endocrine treatment.
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IntroductIon
The fibroblast growth factors (FGFs) make up a large family of ligands that signal 
through cell-surface tyrosine kinase FGF receptors (FGFRs). In humans, 22 distinct FGFs 
and 4 FGFRs have been identified. All FGFs share important similarities, including sig-
nificant sequence homologies at both the DNA and the protein levels (reviewed by 1). 
During embryonic development, FGF signaling has been associated with proliferation, 
migration and differentiation. In adults, FGFs are homeostatic factors that function in 
control of the nervous system, tissue repair, response to injury and tumor angiogenesis 
(reviewed by 1, 2).
The four FGFRs have an extracellular ligand-binding domain, a transmembrane do-
main and a split intracellular tyrosine kinase domain. The ligand-binding domain of 
the receptors is composed of three immunoglobin like domains I, II and III. FGFR1-3 all 
undergo alternative splicing using two alternative exons (IIIb and IIIc) to encode the 
carboxy-terminal half of immunoglobin domain III. These splice variants are expressed 
in a tissue-specific manner with exon IIIb variant expression restricted to epithelial lin-
eages, and exon IIIc variant expression preferentially in mesenchymal lineages. Alterna-
tive splicing also contributes to the receptor binding specificity. Unlike FGFR1-3, FGFR4 
is not alternatively spliced in this region (2, 3), but other variants have been reported 
(4).
FGF17 was identified in our functional screen as a gene causing tamoxifen resistance 
in ZR-75-1 human breast cancer cells (5). Among known FGF family members, the FGF17 
protein shows the highest similarity with FGF8 (6). Together with FGF8 and FGF18 it 
forms a subfamily, having similar gene structures, overlapping patterns of expression 
and receptor binding specificities (1). Over-expression of FGF8 and FGF17 in NIH-3T3 
cells results in a transforming and tumorigenic phenotype (7, 8). Furthermore, FGF8 
expression has been demonstrated to be significantly higher in breast cancer than in 
non-malignant breast tissues (9). No data were available for FGF17 expression in breast 
cancer yet.
In order to investigate the association of FGF17 expression and expression of the 
receptors FGFR1-4 with tamoxifen treatment in breast cancer patients, a retrospective 
study was performed. Gene mRNA levels were measured by real time quantitative re-
verse transcriptase PCR (RT-PCR) in 285 estrogen receptor (ER)-positive frozen primary 
breast tumors from patients who developed recurrent disease that was treated with ta-
moxifen as first-line therapy. This report describes the association of FGF17 and the FGF 
receptors with first-line tamoxifen treatment in patients with recurrent breast cancer.
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Patients
The institutional Medical Ethical Committee approved our study design (MEC 02.953), 
which was carried out according to the Code of Conduct of the Federation of Medical 
Scientific Societies in The Netherlands (http://www.fmwv.nl/). Frozen tumor samples 
were originally submitted to our reference laboratory from regional hospitals for mea-
surements of steroid hormone receptors and have been stored in our tumor bank at the 
Erasmus Medical Center (Rotterdam, The Netherlands). Guidelines for primary treatment 
were similar for all hospitals. All available frozen tumor specimens from female patients 
with breast cancer who entered the clinic during 1979–1995 and from whom detailed 
clinical follow-up was available (10, 11), were processed for mRNA analysis. Further inclu-
sion criteria were: >100 mg frozen tissue available, invasive breast cancer, no previous 
other cancer (except basal cell skin cancer or early-stage cervical cancer stage Ia/Ib), 
no second primary breast tumor at first relapse, no adjuvant systemic hormonal treat-
ment, >30% invasive tumor cell nuclei, and good RNA quality. Samples were rejected 
because of insufficient frozen tumor material (approximately 50%), too low percentage 
tumor cells (approximately 15%) and poor RNA quality (approximately 9%). A total 
of 285 primary, ER-positive breast tumor samples were included in this retrospective 
study. These patients were treated either with breast-conserving surgery (36%) or with 
modified mastectomy (64%). An axillary node dissection was performed in 93% of the 
patients (n = 268, 148 patients node positive). In contrast to current clinical practice, not 
all node-positive patients received adjuvant systemic therapy. This is due to the fact that 
tumors that were surgically removed from 1979 onwards were included in this study, 
and up to around 1990 it was not common clinical practice in The Netherlands to of-
fer adjuvant systemic therapy to all node-positive patients. In total, 211 patients were 
postmenopausal (64% at primary surgery, 74% at start first-line therapy) and all had ER-
positive tumors. ER status was determined by routine ligand-binding assays or enzyme 
immunoassays, and pathological examination was not performed centrally and reflects 
daily clinical practice in the various participating regional hospitals as described previ-
ously (12). None of the patients had received neoadjuvant therapy or were exposed to 
hormonal adjuvant treatment. Half of the patients received adjuvant radiotherapy and 
52 patients were treated with adjuvant chemotherapy (19 patients anthracyclin-based 
(FAC/FEC) and 33 patients non-anthracyclin-based (CMF)). Thirty patients had metasta-
sis at diagnosis or developed distant metastasis (including supraclavicular lymph node 
metastasis) within 1 month after primary surgery.
All patients, including 32 patients with a local recurrence, were treated for recurrent 
disease with first-line tamoxifen therapy (40 mg daily). Median time to treatment was 
28 months. The median age of the patients at the time of primary surgery was 57 years 
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(ranges 26-89 years) and at the start of tamoxifen therapy for recurrent disease 61 years 
(ranges 29-90 years). Patients were routinely followed at the outpatient clinic, generally 
once every 3 weeks during the first 6 months, and in case of objective response approxi-
mately every 6 weeks later on (13). Skin metastases were assessed clinically by palpation 
and documented by photography; lymph node metastases were assessed by palpation 
and sometimes if necessary by ultrasound; lung metastases were routinely followed by 
X-thorax (once every 6-12 weeks), and by CT-thorax where applicable; liver metastases 
were always followed by CT of the liver, in general once every 12 weeks; brain metastases 
were assessed by magnetic resonance imaging if indicated; and bone metastases were 
followed by X-rays (every 6-12 weeks) and bone scan (every 6-12 months) as a standard, 
and by magnetic resonance imaging if indicated. Furthermore, plasma tumor marker 
levels (CA15.3 and/or CA125) were regularly measured. The type of response to tamox-
ifen therapy was recorded as defined by standard Unio Internationale Contra Cancrum 
criteria (14). In total 179 patients, with complete remission (i.e. complete disappearance 
of all metastases, n = 13), partial remission (i.e. at least 50% reduction, n = 39) or with 
stable disease longer than 6 months (n = 127), were classified as patients having clini-
cal benefit (responders) as defined in the manual for clinical research and treatment in 
breast cancer of the European Organization for Research and Treatment of Cancer (15). 
Fifteen patients with stable disease shorter than or equal to 6 months and 91 patients 
having progressive disease (25% or more increase) were classified as non-responders. 
Median follow-up time for treatment of recurrent disease was 42.7 months.
Tissue processing
Primary tumor tissue processing was done as described previously (16). In summary, 
20-60 cryostat sections of 30 µm, corresponding to 30-100 mg, were cut from frozen 
tissues for RNA isolation. To assess the amount of tumor cells relative to the amount of 
surrounding stromal cells, 5 µm sections were cut for hematoxylin and eosin staining, 
before, in between, and after cutting the sections for RNA isolation. For this study, only 
specimen with at least 30% tumor nuclei, distributed uniformly over at least 70% of the 
section area, were included.
RNA isolation, cDNA synthesis and quantification of mRNA
RNA isolation, cDNA synthesis, and quantification of mRNA and quality control checks 
were done as described in detail before (16). RNA samples without distinct rRNA peaks 
or failing to amplify efficiently with the housekeeper primer sets were excluded from 
this study. Real time quantitative RT-PCR was performed using an ABI Prism 7700 
Sequence detection system (Applied Biosystems, Nieuwerkerk a/d IJssel, The Nether-
lands) and Assay-on-Demand kits from Applied Biosystems. The following assays were 
used: Hs00182599_ m1 (FGF17), Hs00241111_m1 (FGFR1), Hs00240796_m1 (FGFR2), 
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Hs00179829_m1 (FGFR3) and Hs00242558_m1 (FGFR4). We used a protocol as recom-
mended by the manufacturer. Quantitative RT-PCR assays for EGFR and ERBB2 have 
previously been described (17). To enable comparison of the mRNA levels in different 
samples, values were normalized using the average expression levels of a set of house-
keeping genes containing PBGD, HPRT and B2M. Levels of the target genes expressed 
relative to this housekeeping set were quantified as follows: mRNA target = 2(mean Ct house-
keeping – mean Ct target) (16). Ct is defined as the detection threshold cycle number.
Statistical analysis
Computations were done with the use of STATA statistical package, release 9.2 (STATA 
Corp., College Station, TX). Differences in levels were assessed with the Mann-Whitney 
U test or Kruskal-Wallis test, including a Wilcoxon-type test for trend, when appropriate. 
In these tests, patient and tumor characteristics were used as grouping variables. The 
strengths of the associations between continuous variables were tested with the Spear-
man rank correlation (rs). To reduce the skewness, most variables were log-transformed 
while ER-α and FGFR3 data were Box-Cox transformed. Logistic regression analysis was 
used to examine the relationship between the mRNA levels measured and clinical ben-
efit of tamoxifen therapy. Odds ratios (ORs) were calculated and presented with their 
95% confidence interval. The likelihood ratio test in logistic regression models was used 
to test for differences. The Cox proportional hazard model was used to calculate the haz-
ard ratio (HR) and 95% confidence interval in the analyses of progression free survival 
(PFS) and post-relapse overall survival. The proportional hazards assumption was tested 
using Schoenfeld residuals. In most cases, tamoxifen treatment is started at the end of 
the disease free interval, except for those patients that were first treated with surgery 
and/or radiotherapy for local recurrence (n = 16). For all cases the starting point of PFS is 
defined as the start of the first line of systemic treatment with tamoxifen for recurrence. 
The endpoint is the first detection of progression of the disease. For visualization, levels 
of FGFR4 were divided into four equal parts. Survival curves were generated using the 
Kaplan & Meier’s (18) method and the log-rank test was used to test for differences. A 
two-sided P-value of < 0.05 was considered statistically significant.
results
Correlations between biological factors
All tissue samples were analyzed for ER and PGR mRNA expression and none tested neg-
ative for ER-α mRNA in concordance with the selection of ER protein-positive samples 
(16). Spearman’s rank correlation revealed associations (P < 0.001) between mRNA levels 
of FGFR4 and FGFR1 (rs = 0.23), FGFR3 (rs = 0.29), and PGR (rs = -0.31). In addition, FGFR1 
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mRNA levels correlated with those of FGF17 (rs = 0.32). ER-α mRNA levels correlated with 
those of PGR (rs = 0.22), FGFR2 (rs = 0.34), and FGFR3 (rs = 0.38).
Association of biological factors with clinicopathological factors
In Table 3.1, the associations of the median mRNA levels of the factors measured with 
clinicopathological factors are shown. ER-α, FGFR2, FGFR3, and FGF17 mRNA levels were 
inversely related with tumor grade. Furthermore, ER-α mRNA expression levels were 
higher in tumors of postmenopausal patients and mRNA levels of FGF17 were inversely 
related with nodal status. PGR mRNA levels varied between histological subtypes, and 
mRNA levels of FGFR1 varied between the different categories of dominant site of 
relapse. None of the mRNA levels determined correlated with tumor size, disease-free 
interval (Table 3.1) or adjuvant systemic treatment (data not shown).
Uni- and multivariate analysis for clinical benefit
The main clinical endpoints of this study were the measurable effect of tamoxifen 
therapy on tumor size (clinical benefit) and the length of PFS of the patients after start 
of first-line therapy for recurrent disease. In univariate logistic regression analysis using 
log-transformed continuous variables, high expression levels of ER-α and PGR predicted 
a favorable clinical benefit (Table 3.2). In contrast, high levels of FGFR4 predicted a worse 
outcome for the patient (OR = 1.22, P = 0.009). For FGF17 and FGFR1-3 no significant 
associations with clinical benefit were observed (Table 3.2). The estimate for FGFR4 was 
similar when patients with a local recurrence were excluded. To further explore the pre-
dictive power of FGFR4, the patients were divided into four equal quarters, ranging from 
low to high FGFR4 mRNA levels. Compared with patients with low tumor mRNA levels 
of FGFR4 (OR set at 1.0), those with high FGFR4 mRNA levels showed a worse outcome 
(OR = 2.92, CI = 1.44-5.92, P = 0.003). Patients with intermediate levels of FGFR4 (Q2 and 
Q3) showed intermediate ORs (Table 3.2). The proportion of patients that experienced 
clinical benefit was 75% (54/72) for those with the lowest, and 51% (36/71) for those 
with the highest FGFR4 mRNA levels.
The predictive value of FGF17 and FGFR1-4 was further studied with multivariable 
logistic regression analysis (Table 3.2). For this analysis, we used the base multivariable 
model including traditional predictive factors (menopausal status, dominant site of 
relapse, disease-free interval, and ER), as described previously for a larger group of 691 
patients treated with first-line tamoxifen for recurrent disease (19), with age and PGR 
added. The traditional prognostic factors ‘nodal status’, ‘tumor size’ and ‘grade’ were not 
included, because they did not have any predictive value as expected in an analysis for 
response to first line therapy for recurrent disease. ‘Adjuvant chemotherapy’ was also 
omitted, since the estimates of our base model were not different with adjuvant therapy 
in- or excluded. FGF17 and FGFR1-4 were separately added as transformed continuous 
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table 3.2 uni- and multivariate logistic regression analysis for clinical benefit of patients receiving 
first-line tamoxifen therapy.
Factor
univariate analysisa multivariate analysisa,b
No of
patients
Clinical
benefit
P OR 95% CI P OR 95% CI
285 63% base model
menopausal statusc 0.038 0.47
premenopausal 74 53% 1 1
postmenopausal 211 66% 0.57 0.33-0.97 0.73 0.30-1.73
agec years 0.16 0.86
≤ 40 18 61% 1 1
41-55 93 54% 1.35 0.48-3.79 1.48 0.48-4.55
56-70 100 67% 0.77 0.27-2.18 1.23 0.32-4.76
>70 74 69% 0.71 0.0.24-2.06 1.13 0.28-4.55
dsr
LRR
bone
viscera
32
146
107
75%
59%
64%
0.20
1
2.09
1.65
0.88-4.97
0.68-4.03
0.18
1
2.36
2.25
0.91-6.10
0.84-6.04
dfI
≤ 1 yr
1-3 yrs
> 3 yrs
74
125
86
42%
70%
71%
< 0.001
1
0.31
0.30
0.17-0.57
0.15-0.57
< 0.001
1
0.30
0.30
0.16-0.56
0.15-0.60
er-α 285 < 0.001 0.81 0.72-0.91 0.004 0.83 0.73-0.94
pgr 285 0.044 0.86 0.74-1.00 0.317 0.92 0.78-1.08
additions to the base modeld
FGF17 285 0.905 0.99 0.83-1.18 0.703 1.04 0.86-1.26
FGFR1 285 0.761 1.03 0.84-1.28 0.787 1.03 0.81-1.31
FGFR2 285 0.732 0.96 0.77-1.20 0.178 1.20 0.92-1.56
FGFR3 285 0.927 1.01 0.82-1.25 0.055 1.28 0.99-1.65
FGFR4 285 0.009 1.22 1.05-1.41 0.031 1.21 1.02-1.43
fgfr4
Q1 72 75% 1 1
Q2 71 58% 0.030 2.20 1.08-4.47 0.089 1.96 0.90-4.27
Q3 71 68% 0.329 1.44 0.69-2.98 0.535 1.28 0.58-2.81
Q4 71 51% 0.003 2.92 1.44-5.92 0.021 2.61 1.15-5.87
a The probability of non-response has been modeled.
 b Biological factors were separately introduced as transformed continuous variable to the base multivariable model that included the factors 
menopausal status, age, DSR dominant site of relapse, DFI disease-free interval, and ER-α estrogen receptor alpha and PGR progesterone receptor 
mRNA levels as transformed continuous variables.
c At start of first-line therapy for recurrent disease.
d Factors added separately to the base model.
Abbreviations: OR, odds ratio; CI, confidence interval
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table 3.3 uni- and multivariate cox regression analysis for progression-free survival of patients 
receiving first-line tamoxifen therapy.
Factor
univariate analysis multivariate analysisa
No of
patients
P HR 95% CI P HR 95% CI
285 base model
menopausal statusb 0.14 0.081
premenopausal 74 1 1
postmenopausal 211 0.81 0.62-1.07 1.46 0.95-2.23
ageb years 0.025 0.051
≤ 40 18 1 1
41-55 93 0.76 0.46-1.26 0.60 0.35-1.03
56-70 100 0.61 0.36-1.01 0.42 0.22-0.80
> 70 74 0.51 0.30-0.86 0.38 0.20-0.74
dsr
LRR
bone
viscera
32
146
107
0.20
1
1.43
1.30
0.95-2.17
0.85-1.99
0.35
1
1.26
1.38
0.81-1.94
0.88-2.18
dfI
≤ 1 yr
1-3 yr
> 3 yr
74
125
86
0.005
1
0.72
0.58
0.54-0.97
0.42-0.80
0.022
1
0.74
0.62
0.54-1.00
0.44-0.87
er-α 285 < 0.001 0.91 0.86-0.95 0.028 0.94 0.88-0.99
pgr 285 0.002 0.89 0.83-0.96 0.024 0.91 0.85-0.99
additions to the base modelc
FGF17 285 0.802 1.01 0.93-1.10 0.474 1.03 0.95-1.13
FGFR1 285 0.077 1.10 0.99-1.23 0.054 1.12 1.00-1.26
FGFR2 285 0.090 0.90 0.79-1.02 0.394 0.94 0.83-1.08
FGFR3 285 0.233 0.94 0.84-1.04 0.656 1.03 0.91-1.16
FGFR4 285 < 0.001 1.18 1.09-1.27 < 0.001 1.17 1.08-1.27
fgfr4
Q1 72 1 1
Q2 71 0.208 1.25 0.88-1.77 0.468 1.15 0.79-1.67
Q3 71 0.357 1.18 0.83-1.66 0.470 1.14 0.80-1.62
Q4 71 <.001 2.24 1.58-3.16 <.001 2.11 1.43-3.12
a Biological factors were separately introduced as log-transformed continuous variable to the base multivariable model that included the factors 
menopausal status, age, DSR dominant site of relapse, DFI disease-free interval, and ER-α estrogen receptor alpha and PGR progesterone receptor 
mRNA levels as transformed continuous variables.
b At start of first-line therapy for recurrent disease.
c Factors added separately to the base model.
Abbreviations: HR, hazard ratio
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variables to the base model. These analyses showed that the predictive value of FGFR4 
(OR = 1.21, P = 0.031) for clinical benefit was independent from the traditional predictive 
factors of the base model (Table 3.2).
Analysis for progression-free and post-relapse overall survival
In univariate analysis using log-transformed continuous variables, high tumor levels of 
ER-α and PGR mRNA were correlated with longer PFS and thus with better outcome for 
the patient (Table 3.3). On the other hand, high mRNA levels of FGFR4 were significantly 
associated with shorter PFS (log-transformed continuous, HR = 1.18, P < 0.001). To allow 
visualization by Kaplan-Meier plots, patients were divided into four equal quarts accord-
ing to their FGFR4 mRNA levels. Patients having low FGFR4 mRNA levels (quarter 1) had 
a median PFS of more than twice the PFS of patients having high FGFR4 mRNA levels 
(quarter 4) (14 vs. 6 months Figure 3.1A). Post-relapse overall survival (Figure 3.1B) was 
also significantly better in patients with low FGFR4 mRNA levels. In multivariable analy-
sis, the predictive value of FGFR4 was independent of the traditional predictive factors 
(Table 3.3). When divided in quarts, the hazards ratios compared with the lowest quartile 
(Q1) were 1.15 (Q2), 1.14 (Q3) and 2.11 (Q4). The proportional hazards assumption was 
not violated for FGFR4.
dIscussIon
Recently, we have identified FGF17 in a functional screen for genes responsible for 
tamoxifen resistance in a human breast cancer cell line (5). FGF17 is predominantly 
expressed in the brain and the nervous system and no data were available for its ex-
pression in breast cancer until now. In contrast, other FGFs and the FGFRs have been 
reported to be expressed and to have a potential role in breast cancer (reviewed by 20, 
21). Furthermore, FGF2 has been linked to tumor aggressiveness (22, 23) and FGFR3 and 
FGF5 to metastatic preferences of breast cancer (24, 25).
In the current exploratory study, quantitative RT-PCR was used to evaluate whether 
mRNA expression levels of FGF17 and the receptors FGFR1-4 in primary tumors can 
predict the outcome of first-line tamoxifen treatment. The endpoints of this study were 
clinical benefit of the therapy and PFS in patients with recurrent breast cancer. Because 
of the retrospective nature of this study, we have defined the type of response strictly 
beforehand. The size of the metastases or the occurrence of new lesions was used as 
objective measures of treatment effect. We included only hormone-naive patients to 
exclude acquired therapy resistance to tamoxifen.
Our study shows that FGF17 mRNA levels did not associate with clinical benefit and 
PFS of patients treated with tamoxifen. In contrast, increasing levels of its receptor FGFR4 
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were related with a higher probability of tamoxifen failure. In multivariable analysis, high 
tumor levels of FGFR4 provided additional predictive information, independent of the 
traditional predictive factors menopausal status, dominant site of relapse, disease free 
interval, ER, and PGR status. Moreover, addition of the mRNA levels of EGFR and ERBB2 
(HER2) as variables to the base model did not alter the estimates for FGFR4 for PFS or 
clinical benefit (Table 3.4). No significant correlation was observed with disease-free 
survival in this patient series (Table 3.1), nor in an independent set of 604 node-negative 
B 
 
 
 
Figure 3.1 
 
 
 
 
 
 
 
Figure 3.1 Kaplan-Meier curves of progression-free survival (panel A) and post-relapse overall survival (panel B) for advanced breast cancer 
patients after start of first-line tamoxifen therapy as a function of the FGFR4 mRNA levels in quarters. Patients at risk are indicated.
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breast cancer patients (data not shown), indicating that FGFR4 mRNA levels are not 
merely associated with prognosis. For FGFR4, gene amplification and relatively high 
expression levels have been found in breast cancer (26, 27). In addition, a germ line 
polymorphism in this gene, resulting in expression of FGFR4 variants containing either 
glycine (Gly388) or arginine (Arg388) at codon 388, has been identified (28). However, there 
has been some debate whether the Arg388 allele is relevant for breast cancer prognosis 
(28-32). Furthermore, Thussbas et al. (32) reported a survival difference favoring FGFR4 
wild type in patients treated with adjuvant chemotherapy. In addition, no significant 
survival difference between the variants was seen in patients treated with adjuvant en-
docrine therapy. Future analysis of this polymorphism in our patient series may establish 
its predictive value.
FGFR4 adds to an expanding list of biological factors which provide predictive infor-
mation for tamoxifen treatment of breast cancer (33). Prominent examples are uPA/PAI-1 
(19, 34), cyclin E (35), HOXB13/IL17BR (36, 37), the 81 gene signature (38), and BCAR1, a 
gene identified in another functional screen (39).
The question whether FGFR4 association with development of tamoxifen resistance is 
caused in a direct manner remains to be solved. The observation that FGF17 in epithelial 
lineages mainly activates FGFR4 (40), supports the theory that the biological effects 
seen in our functional screen were caused by activation of this particular receptor. In 
concordance with this hypothesis, we have confirmed expression of FGFR4 (at levels 
comparable with the housekeepers) and the other FGFR family members in our cell 
model using quantitative RT-PCR analysis (unpublished results). The absence of associa-
tion between FGF17 and FGFR4 levels in the breast tumors may be explained by the 
balance between the receptor concentration and the amount and affinity of all ligands. 
Activation of FGFRs may lead to activation of the MAPK and the PI3K/AKT pathways (41). 
Increasing evidence indicates that changes occurring in growth factor signaling path-
ways, as currently well documented for EGFR and ERBB2, may dramatically influence 
table 3.4 fgfr4 is independent of egfr and erbb2.
clinical benefita progression-free survivalb
Factor P OR 95% CI P HR 95% CI
EGFRc 0.186 0.84 0.64-1.09 0.468 0.96 0.85-1.08
ERBB2d 0.545 1.28 0.57-2.86 0.003 1.81 1.22-2.69
FGFR4c 0.045 1.20 1.00-1.43 0.002 1.15 1.05-1.25
a Multivariable logistic regression analysis for clinical benefit of patients receiving first-line tamoxifen therapy with simultaneous addition of 
the factors and corrected for the base model as detailed in Table 2.
b Multivariable Cox regression analysis for progression-free survival of patients receiving first-line tamoxifen therapy with simultaneous 
addition of the factors and corrected for the base model as detailed in Table 3.
c Factor added as log-transformed continuous variable.
d Factor added as dichotomized variable representing high (14% of the patients) and low levels of mRNA.
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steroid hormone action and may be critical to anti-hormone-resistant breast cancer cell 
growth (42-48).
In conclusion, the established association between FGFR4 mRNA levels and clinical 
benefit of therapy suggests that FGFR4 plays a role in the biological response of the 
tumor to tamoxifen treatment. As altered FGF signaling causes tamoxifen resistance in 
vitro, this pathway could be a valuable target in the treatment of breast cancer patients 
resistant to endocrine treatment.
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abstract
Purpose: Two genes, TSC22 domain family, member 1 (TSC22D1) and prosaposin (PSAP) 
were identified in an in vitro functional screen for genes having a causative role in ta-
moxifen resistance. These genes were also present in our previously established 81-gene 
signature for resistance to first-line tamoxifen therapy. The aim of this study was to in-
vestigate the predictive value of these genes for tamoxifen therapy failure in patients 
with recurrent breast cancer. Experimental Design: The mRNA levels of TSC22D1 and 
PSAP were analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) in 
223 estrogen receptor-positive primary breast tumors of patients with recurrent disease 
treated with first-line tamoxifen therapy. The main objective of this study was the length 
of progression-free survival (PFS). Results: High mRNA levels of TSC22D1 and PSAP were 
significantly associated with shorter PFS and both were independent of the traditional 
predictive factors (HR = 1.30, 95% CI = 1.04-1.64 P = 0.023; and HR = 1.40, 95% CI = 
1.03-1.88, P = 0.029, respectively). In multivariate analysis, patients with high mRNA 
levels of both genes associated significantly with no clinical benefit (OR = 0.19, 95% 
CI = 0.06-0.62, P = 0.006) and had the shortest PFS (HR = 2.05, 95% CI = 1.29-3.25, P = 
0.002). Conclusion: These results confirm our previous in vitro and tumor-related findings 
and are indicative for the failure of tamoxifen treatment in breast-cancer patients. Both 
TSC22D1 and PSAP are associated with clinical outcome and may have a functional role 
in therapy resistance.
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IntroductIon
Breast cancer is the most common malignancy among women in the Western world. For 
more than 30 years, the anti-estrogen tamoxifen has been used for the treatment of es-
trogen receptor (ER)-positive breast cancer. However, only half of the patients who have 
ER-positive tumors respond to tamoxifen therapy, while the other half show intrinsic 
resistance. Moreover, patients who initially respond to therapy, will ultimately acquire 
resistance during long-term treatment.
In the last decades, various studies have been performed to identify biological factors 
that predict the success of tamoxifen treatment (1). Several molecular signatures have 
been reported to associate with tamoxifen therapy efficacy. A 21-gene (2) and a 2-gene 
signature, HOXB13/IL17BR (3), were correlated with disease-free survival in patients 
treated with tamoxifen in the adjuvant setting. In a genome-wide microarray study, we 
defined an 81-gene signature for tamoxifen therapy failure in patients with advanced 
disease (4). Although these gene signatures classify for prediction of clinical outcome, 
they do not necessarily identify those genes that are functionally responsible for treat-
ment resistance.
Therefore, we performed a different approach, namely retroviral transduction of 
cDNA libraries, to identify genes causing tamoxifen resistance. In this in vitro functional 
screen, a set of 73 different genes has been identified. Using stringent selection crite-
ria 7 genes have been reported to cause tamoxifen resistance (5). The latter included 
epidermal growth factor receptor (EGFR), Neuregulin 1 (NRG1), platelet-derived growth 
factor receptor-α (PDGFRA), platelet-derived growth factor receptor-β (PDGFRB), colony-
stimulating factor 1 receptor (CSF1R), fibroblast growth factor 17 (FGF17), and breast 
cancer anti-estrogen resistance 4 (BCAR4). From these, EGFR, BCAR4, and NRG1 have 
already been related with tamoxifen resistance. High levels of EGFR and BCAR4 promote 
anti-estrogen resistant proliferation of breast-cancer cells in vitro (5-7). High expression 
levels of NRG1 changed MCF-7 breast cancer cells into an estrogen-independent and 
antiestrogen-resistant state, which was later mimicked in a transgenic mice model (8). 
In addition, HER2 an established marker and a proven target for patients resistant to 
tamoxifen therapy, was amongst the remaining 66 discovered genes. However, the re-
maining genes need further validation to establish their role in resistance in vitro and 
their association with therapy failure in clinical breast cancer.
We propose that those genes identified with two independent approaches are in-
teresting candidates as predictive markers and/or targets for treatment. Interestingly, 
only two genes, TSC22D1 (OMIM 607715; 13q14) and PSAP (OMIM 176801; 10q21-q22), 
were identified that were both highly expressed in tumors resistant to tamoxifen in our 
microarray study and were recovered from our functional screen.
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In the current study, we investigated the clinical relevance of the TSC22D1 and PSAP in 
tamoxifen resistance with a third platform. To this end, gene mRNA levels were measured 
by qRT-PCR in 223 ER-positive primary breast tumors from patients who developed re-
current disease that was treated with tamoxifen as first-line therapy.
patIents and methods
Patients
This retrospective study has been approved by the medical ethics committee of the 
Erasmus MC Rotterdam, The Netherlands (MEC 02.953). Total RNA was isolated from 
frozen primary breast tumors of women who entered the clinic between 1981 and 1995 
and from whom detailed clinical follow-up information was available (9, 10). The present 
study, in which coded tumor tissues were used, was performed in accordance with the 
Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands 
(http://www.fmwv.nl). Specimens were excluded when patients had received (neo)ad-
juvant hormonal therapy, when there was insufficient frozen tumor material, less than 
30% epithelial tumor cells, poor RNA quality, or missing values for TSC22D1 or PSAP 
mRNA expression levels. In total, ER-positive breast tumors of 223 patients who devel-
oped advanced disease treated with first-line tamoxifen therapy were included in this 
study. ER and progesterone receptor (PgR) protein status of the tumors was determined 
by routine ligand-binding assays or enzyme immunoassays. Eighty-five patients (38%) 
underwent breast conserving lumpectomy and 138 patients (62%) modified mastec-
tomy. Ninety-two percent of the patients underwent an axillary-node dissection (n = 
206) and 110 patients were node positive (49%) at the time of surgical removal of the 
primary tumor.
All patients, including 13 patients with a local recurrence, were treated with first-line 
tamoxifen therapy (40 mg daily) for advanced disease. Adjuvant radiotherapy was given 
to 58% of the patients and 34 patients (15%) were treated with adjuvant chemotherapy 
(16 patients anthracyclin-based (FAC/FEC) and 18 patients non-anthracyclin-based 
(CMF)). Median time to recurrence was 26 months. Median follow-up for recurrent dis-
ease of patients alive and treated with tamoxifen was 44 months. The median age of 
the patients at the time of primary surgery was 59 years (range, 26-89 years) and at the 
start of first-line tamoxifen therapy for recurrent disease 62 years (range, 29-90 years). 
In total, 168 patients were postmenopausal at start of therapy. Twenty-five patients 
had metastasis at diagnosis or developed distant metastasis (including supraclavicular 
lymph node metastasis) within 1 month after primary surgery.
The type of response to tamoxifen therapy was recorded as defined by standard Union 
Internationale Contre Cancer criteria (11). No clinical benefit occurred in 91 patients 
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(41%) of whom 81 patients had progressive disease and 10 patients showed stable 
disease shorter than 6 months. One hundred thirty-two patients (59%) showed clini-
cal benefit from first-line tamoxifen therapy, of whom 11 patients showed a complete 
remission, 34 patients showed partial remission, and 87 patients showed stable disease 
longer than 6 months.
RNA isolation and quantitative RT-PCR
Tissue processing, RNA isolation, cDNA synthesis and quantitative real-time reverse-
transcriptase polymerase chain reaction were performed as described previously 
(9). The qRT-PCRs were performed on an ABI Prism 7700 Sequence Detection System 
(Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands), according to the recom-
mended protocol. Commercially available Assay-on-Demand kits (Applied Biosystems) 
were used for TSC22D1 (Hs00394659_m1) and PSAP (Hs00358165_m1). Forty rounds of 
amplification were performed according to the supplier’s protocol and at the end of 
the amplification fluorescent signals of the Taqman probes were used to generate Cycle 
threshold (Ct) values from which mRNA expression levels were calculated. Expression 
levels of TSC22D1 and PSAP were normalized against average expression levels of three 
housekeeping genes, i.e., porphobilinogen deaminase (PBGD), hypoxanthine-guanine 
phospho-ribosyltransferase (HPRT) and β-2-microglobulin (B2M) (9).
Data analysis and statistics
Differences in mRNA levels were assessed with the Mann-Whitney U test or Kruskal-
Wallis test when appropriate. In these tests, patient and tumor characteristics were used 
as grouping variables. Associations between continuous variables were tested with 
the Spearman rank correlation (Rs). Cox proportional-hazards models were applied to 
compute the hazard ratio (HR), which correlates expression levels of the variables with 
progression-free survival. Progression-free survival was defined as the time between 
start of treatment with tamoxifen as first-line systemic therapy for recurrent disease and 
the occurrence of disease progression. In multivariate analysis, Cox regression analysis 
was applied to determine whether TSC22D1 and PSAP had a predictive value and was 
independent when added to the base model of the traditional predictive factors age, 
menopausal status, disease-free interval (DFI), dominant site of relapse (DSR), and log ER 
and log PgR mRNA levels (12). The proportional hazards assumption was not violated for 
TSC22D1 and PSAP in any of these analyses. Logistic-regression analysis was performed 
to calculate the odds ratio (OR) that defines the relation between expression levels and 
clinical benefit of tamoxifen therapy. Both HR and OR were calculated on log-transformed 
variables and were represented with their 95% confidence interval (95% CI).
Only when the test for trend of a continuous variable was statistically significant a 
search for a cutoff point was considered justified. To define cutoff points, we used iso-
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tonic regression analysis to find the points where the monotonic relationship between 
the measured level and the hazard rate showed a distinct change. On the basis of these 
cutoff points, survival curves were generated using the method of Kaplan and Meier and 
a log-rank test was used to test for differences. Computations were performed with the 
STATA statistical package, release 10 (STATA Corp., College Station, TX). All P-values were 
two-sided and P < 0.05 was considered statistically significant.
results
Associations of TSC22 and PSAP with clinicopathological factors
In this study, TSC22D1 and PSAP mRNA expression levels were measured in 223 pri-
mary breast tumors using qRT-PCR. Median expression levels of TSC22D1 and PSAP, 
their interquartile range, and their association with patient and tumor characteristics are 
shown in Table 4.1 TSC22D1 and PSAP expression levels did not have a relationship with 
menopausal status, tumor size, nodal status, tumor grade, nor with histological subtype 
(Table 4.1). All tissues were ER positive at the protein level and in agreement none of 
the samples tested negative for ER-α mRNA levels (9). Both TSC22D1 and PSAP mRNA 
levels had an inverse correlation with ER and PgR at mRNA levels (Rs = -0.06 and -0.16 for 
TSC22D1 and Rs = -0.03 and -0.09 for PSAP, respectively). At protein levels, these inverse 
correlations were significant (Rs = -0.16 and -0.26 for TSC22D1 and Rs = -0.15 and -0.17 
for PSAP, respectively). Moreover, at mRNA levels TSC22D1 was significantly (P < 0.001) 
correlated with PSAP (Rs = 0.33), EGFR (Rs = 0.37), and ERBB2 (Rs= 0.24). Finally, PSAP had 
a significant (P < 0.001) correlation with EGFR (Rs = 0.22), but not with ERBB2.
Association of TSC22D1 and PSAP expression levels with progression-free survival 
and clinical benefit
Clinical endpoint of this study was progression after start of first-line tamoxifen therapy. 
TSC22D1 and PSAP mRNA levels, as univariate continuous log-transformed variables, 
were significantly associated with shorter PFS (HR = 1.39, 95% CI = 1.12-1.72, P = 0.003 
and HR = 1.51, 95% CI = 1.13-2.02, P = 0.006, respectively) (Table 4.2). TSC22D1 expres-
sion was also significantly associated with clinical benefit to tamoxifen therapy (OR = 
0.64, 95% CI = 0.42-0.98, P = 0.042), while PSAP was not.
The significant findings of TSC22D1 and PSAP for PFS as continuous variable in univari-
ate analysis justified the search for predictive cutoff points. Cutoff points for TSC22D1 
and PSAP were 0.042 and 0.378, respectively. Patient groups with the highest levels of 
TSC22D1 or PSAP had a worse outcome for first-line tamoxifen treatment (HR = 1.72, 
95% CI = 1.26-2.33, P < 0.001; HR= 1.79, 95% CI = 1.23-2.59, P = 0.002, respectively) 
(Table 4.2). The predictive values of dichotomized TSC22D1 and PSAP are visualized 
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table 4.1 associations of tsc22d1 and psap mrna levels with clinicopathological factors
  TSC22D1 PSAP
 no. patients % median Δ§ p * median Δ§ p *
age ( years)† 0.033 ║ 0.215 ║
<40 23 10 0.074 0.048 0.624 0.357
41-55 74 33 0.061 0.056 0.668 0.611
56-70 82 37 0.063 0.068 0.711 0.607
>70 44 20 0.046 0.059 0.784 0.581
menopausal status† 0.319 †† 0.670 ††
Premenopausal 73 33 0.069 0.047 0.648 0.592
Postmenopausal 150 67 0.060 0.068 0.741 0.565
tumor size 0.154 ‡ 0.236 ‡
pT1, <2cm 63 28 0.061 0.058 0.744 0.557
pT2, >2-5cm 130 58 0.066 0.061 0.692 0.592
pT3, >5cm + pT4 30 13 0.049 0.059 0.669 0.669
lymph nodes involved 0.652 ‡ 0.111 ‡
0 98 47 0.062 0.068 0.741 0.594
1-3 52 25 0.061 0.056 0.601 0.513
>3 58 28 0.059 0.06 0.693 0.557
grade 0.912 ‡ 0.763 ‡
Poor 125 56 0.061 0.065 0.704 0.664
Unkown 71 32 0.063 0.056 0.728 0.568
Good/moderate 27 12 0.059 0.064 0.652 0.338
histological type 0.411 ‡ 0.187 ‡
IDC 134 60 0.061 0.065 0.733 0.572
ILC 24 11 0.043 0.041 0.654 0.371
DCIS + IDC 13 6 0.068 0.016 0,637 0,580
other/unknown 52 23 0.068 0.063
pgr protein status** <0.001 ║ 0.010 ║
PgR low 37 17 0.089 0.094 0.857 0.695
PgR high 183 83 0.059 0.052 0.688 0.581
response tamoxifen first-line treatment 0.021 ‡ 0.268 ‡
Complete response 11 5 0.037 0.034 0.473 0.830
Partial response 34 15 0.045 0.073 0.744 0.603
Stable disease > 6 months 87 39 0.060 0.051 0.649 0.521
Stable disease < 6 months 10 5 0.098 0.045 0.919 0.673
Progressive disease 81 36 0.063 0.063  0.758 0.532  
§ Interquartile range (q75-q25).
* Two-sided P-value.
† at primary surgery
║ Spearman rank correlation.
†† Mann-Whitney U test.
‡ Kruskal-Wallis test
** In 3 samples PgR status was unknown
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table 4.2 cox uni- and multivariate analysis for progression-free survival of patients receiving first-line tamoxifen 
therapy
univariate analysis multivariate analysis
factor of base model
no. of 
patients
% hr 95% cI p hr 95% cI p
age (years) * 0.041 0.041
<40 14 6 1 1
41-55 69 31 0.74 0.41 1.32 0.63 0.34 1.16
56-70 81 36 0.65 0.37 1.16 0.48 0.23 1.00
>70 59 26 0.48 0.26 0.87 0.35 0.16 0.75
menopausal status * 0.337 0.112
Premenopausal 55 25 1 1
Postmenopausal 168 75 0.85 0.62 1.17 1.47 0.91 2.36
disease-free-Interval <0.001 <0.001
< 1year 60 27 1 1
1-3 years 99 44 0.63 0.45 0.87 0.58 0.42 0.82
>3 years 64 29 0.46 0.31 0.67 0.44 0.30 0.65
dominant site of relapse 0.446 0.550
viscera 84 38 1 1
Bone 119 53 1.05 0.78 1.41 0.91 0.66 1.24
LRR 20 9 0.76 0.45 1.29 0.74 0.42 1.30
er-α mrna level 223 100 0.89 0.83 0.95 <0.001 0.91 0.84 0.98 0.014
pgr mrna level 223 100 0.89 0.83 0.96 0.002 0.89 0.82 0.97 0.005
factors analysed        additions to the base model
TSC22D1           
continuous variable 223 100 1.39 1.12 1.72 0.003 1.30 1.04 1.64 0.023
cutoff point for pfs ‡
low 70 31 1 1
high 153 69 1.72 1.26 2.33 <0.001 1.60 1.16 2.19 0.004
PSAP           
continuous variable 223 100 1.51 1.13 2.02 0.006 1.40 1.03 1.88 0.029
cutoff point for pfs ‡
low 41 18 1 1
high 182 82 1.79 1.23 2.59 0.002 1.63 1.12 2.37 0.001
TSC22D1 & PSAP           
cutoff point for pfs ‡
Group 1 (both genes low) 27 12 1 1
Group 2 (one gene low) 57 26 1.54 0.93 2.54 0.09 1.49 0.9 2.47 0.12
Group 3 (both genes high) 139 62 2.29 1.46 3.61 <0.001 2.05 1.29 3.25 0.002
* At start of first-line therapy for recurrent disease.
‡ cutoff points were determined at 0.042 for TSC22D1 and 0.378 for PSAP
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with Kaplan-Meier curves (Figure 4.1). The differences in median PFS were 7.5 and 7 
months between patients with high and patients with low expression levels of TSC22D1 
or PSAP, respectively. Furthermore, TSC22D1 dichotomized at the cutoff point was also 
significantly associated with clinical benefit to tamoxifen therapy (OR = 0.38, 95% CI = 
0.20-0.71, P = 0.002).
In multivariate analysis, both factors analyzed as continuous and dichotomized vari-
able were significantly associated with PFS (Table 4.2), showing that they are indepen-
dent from the traditional predictive factors (age, menopausal status, DSR, DFI, ER and 
PgR levels). When adjuvant chemotherapy was added to the base model, the estimates 
for TSC22D1 and PSAP did not change indicating that possible chemical castration prior 
to endocrine therapy has no significant impact on these results. In multivariate analysis 
for clinical benefit, dichotomized TSC22D1 levels showed a significant relation with clini-
cal benefit (OR = 0.39, 95% CI = 0.19-0.78, P = 0.008).
In a subsequent exploratory analysis, we divided our patient group into three subsets 
on the basis of their mRNA levels for both TSC22D1 and PSAP (both genes low (group 
1), one gene low (group 2), and both genes high (group 3)). Compared with the patients 
having low mRNA levels for both genes (HR set at 1.0), those with high mRNA levels 
for both genes (62% of the patients) had a significantly shorter PFS (HR = 2.29, 95% CI 
= 1.46-3.61, P < 0.001). Patients having low levels for one gene (26% of the patients) 
showed an intermediate HR (1.54, P = 0.09, 95% CI = 0.93-2.54) (Table 4.2). The difference 
in median PFS between patient groups having high versus low levels for both genes was 
9 months (Figure 4.2). Multivariate analysis for PFS (Table 4.2) and clinical benefit (OR 
intermediate = 0.30, 95% CI = 0.08-1.05, P = 0.06; OR high = 0.19, 95% CI = 0.06-0.62, P = 
0.006) showed that these results are independent from traditional predictive factors.
dIscussIon
Recently, we performed a genome wide screen in breast tumor samples to uncover a set 
of markers predictive for the type of response to endocrine therapy (4) and a functional 
screen using retroviral transduction of breast cancer cells for finding genes involved in 
tamoxifen resistance (5). In the first approach, we have identified 81 genes predicting 
resistance to tamoxifen therapy and in the latter approach we found 73 candidate genes 
possibly having a causative role in tamoxifen resistance. Combining the results of both 
approaches, two overlapping genes, PSAP and TSC22D1, were identified.
In the current study, we used qRT-PCR as a third method to validate the predictive 
value of TSC22D1 and PSAP in tamoxifen therapy. The patient cohort in this study is clini-
cally relevant because it included a large group of patients with stable disease. We in-
vestigated whether the expression levels of TSC22D1 and PSAP in primary breast tumors 
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Figure 4.1 Kaplan-Meier curves of progression-free survival for advanced breast cancer patients after start of first-line tamoxifen therapy as a 
function of TSC22D1 (A) and PSAP (B) mRNA levels. On the basis of cutpoint analyses, patients were divided into two groups, having low or high 
mRNA levels. Patients at risk are indicated.
:
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could predict the outcome of first-line tamoxifen treatment in patients with advanced 
disease. Our results confirm that patients having high mRNA levels of TSC22D1 and/or 
PSAP have a shorter PFS compared with patients having low levels of these genes.
TSC22D1 encodes a leucine-zipper transcription factor and belongs to the large family 
of early response genes. It was originally isolated as a Transforming Growth Factor, beta-1 
(TGFβ) inducible gene in mouse osteoblasts (13). TSC22D1 was proposed as a tumor-
suppressor gene because it participates in growth inhibition of brain tumors, salivary-
gland tumors and prostate cancers (14-16). TSC22D1 was found to be downregulated 
in the presence of estrogens in MCF7 breast cancer cells (17) which was in concordance 
with our Spearman rank correlation data. Expression of the gene was shown to be up-
regulated through progesterone in growth-inhibited breast cancer cells (18).
With regard to TGFβ signaling it was shown that TSC22D1 enhanced TGFβ signaling in 
U973 cells by interaction with SMAD4 (19). Furthermore, TSC22D1 increased levels of Cy-
clin-dependent Kinase Inhibitor 1A (CDKN1A, also known as p21 or CIP1), a downstream 
component of TGFβ, in colon carcinoma cells (20). In addition, TGFβ is a well known 
inhibitor of cell proliferation, which can be activated by the presence of tamoxifen (21). 
These data support an inhibitory effect of TSC22D1 on tumor proliferation and seem to 
be in contrast with the fact that high levels of TSC22D1 are associated with tamoxifen re-
sistance. However, it has been described that TGFβ can turn into a promoter of progres-
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Figure 4.2 Kaplan-Meier curve of progression-free survival for advanced breast cancer patients after start of first-line tamoxifen therapy as a 
function of combined TSC22D1 and PSAP mRNA levels. Patients were divided into three groups having low levels for both genes (group 1), low 
levels for TSC22D1 or PSAP (group 2), and high levels for both genes (group 3). Patients at risk are indicated.
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sion in later tumor stages and can stimulate tumor angiogenesis, extracellular matrix 
degradation, inhibition of antitumor immune response, and epithelial-to-mesenchymal 
transition (22).
PSAP is a lysosomal precursor protein of the saposins A, B, C, and D. PSAP has been 
reported to be present in conditioned media from the ER negative MDA-MB-231 as well 
as the ER positive MCF-7 breast cancer cell lines and in SV40 transformed normal HBL100 
breast cells. Besides that, it also exists uncleaved in many biological fluids, including hu-
man milk (23, 24). Estrogens have been reported to stimulate PSAP production in MCF-7 
cells. Moreover, PSAP interacts with procathepsin D in human breast cancer cells (25, 26), 
suggesting a role in tumor invasiveness and metastasis. Misasi et al. have demonstrated 
an anti-apoptotic effect of PSAP in neuronal as well as non-neuronal cells (27, 28). They 
have shown that PSAP activates Mitogen-activated Protein Kinase 1 and 3 (ERK-2 and -1) 
and spingosine kinase, and they propose a possible role in cell survival for the MAPK and 
PI3K-Akt pathways through which these genes exert their function. Interestingly, both 
pathways have previously been reported to be associated with tamoxifen resistance (29, 
30). The latter supports our observed association of high levels of PSAP with tamoxifen 
treatment failure.
Almost two-thirds of the patients show high expression levels of both PSAP and 
TSC22D1. This group has an even poorer treatment outcome. The relative high percent-
age of patients with high levels of both genes may be explained by CDKN1A. It has been 
reported that TSC22D1 increase CDKN1A levels. Besides its well-known tumor-suppres-
sive effects, high levels of CDKN1A have also been reported to have an unfavorable effect 
in anticancer treatment (31). In permanently growth-inhibited tumor cells, a state that 
bears resemblance to tamoxifen treatment, CDKN1A has been shown to induce genes 
having an anti-apoptotic or mitogenic activity, including PSAP (32, 33). Furthermore, 
this indicates that upregulation of CDKN1A also supports the possible tumor-promoting 
capabilities of TSC22D1.
In the present study, qRT-PCR analysis of mRNA levels of TSC22D1 and PSAP in primary 
breast-cancer specimens validates our previous genome wide and in vitro findings of 
these genes being associated with tamoxifen resistance. Since the mechanisms of ac-
tion of PSAP and TSC22D1 have not been well characterized, the biological processes 
involved in tamoxifen resistance remain to be elucidated. As discussed above, several 
lines of evidence have been reported already. It would be intriguing though to unravel 
the precise role of these genes in resistance with respect to the clinical significance in 
breast cancer.
We showed an association of high expression levels for both genes with failure of 
tamoxifen treatment in patients with recurrent breast cancer. On the basis of our func-
tional screen, both genes have a putative causative role in therapy resistance and this 
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may give new perspectives on biological pathways containing new drugable targets for 
tamoxifen therapy.
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abstract
Breast Cancer Antiestrogen Resistance gene 4 (BCAR4) has been identified in a func-
tional screen as a gene causing tamoxifen resistance in human breast cancer cells. Here 
we describe further characterization of this novel gene. Ectopic expression of BCAR4 in 
ZR-75-1 resulted in cell proliferation both in the absence of estrogen and in the presence 
of various antiestrogens. The gene also caused ICI182,780-resistant proliferation of 
MCF7 cells when over-expressed. Two different conserved primate homologues (rhesus 
monkey and African green monkey) induced tamoxifen-resistant cell proliferation when 
transfected to ZR-75-1 cells as well. Using fusion proteins of BCAR4 with FLAG-tags the 
protein was localized to the cytoplasm and to a lesser extent to the cell membranes. 
Injection of ZR-75-1 cells expressing BCAR4 into nude mice resulted in rapidly growing 
tumors, whereas the parental cell line was unable to do so. Proliferation assays in the 
presence of small-molecule inhibitors indicated a possible role for mitogen-activated 
protein kinase 14 (p38) in BCAR4 signaling. In conclusion, BCAR4 is a strong transform-
ing gene which causes estrogen independence and induces solid tumors in nude mice. 
These results indicate that the signaling pathway that is activated by BCAR4 may play a 
role in breast cancer progression.
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IntroductIon
Breast cancer is the most frequent malignancy in women in the western world. It has 
been well established that the hormone estrogen plays a significant role in breast-
cancer development and progression. Selective estrogen receptor (ER) modulators, like 
tamoxifen, have been the most commonly used hormonal therapy for ER-positive breast 
cancer during the last three decades. However, resistance to this therapy presents a ma-
jor challenge in disease management and are the subject of active investigation.
To identify genes involved in tamoxifen resistance, we have used retroviral trans-
duction of cDNA libraries into the ZR-75-1 human breast cancer cell line (1). With this 
approach, we have identified 73 genes with a possible role in tamoxifen resistance. After 
application of stringent selection criteria, 7 genes were stated to have a causative role in 
resistance. Among this set were Epidermal Growth Factor Receptor (EGFR) and Neuregu-
lin 1 (NRG1), which already have been shown to be related with tamoxifen resistance 
(2-4). In addition, we identified a novel gene designated as BCAR4. Ectopic expression 
of BCAR4 induced tamoxifen-resistant proliferation in the tamoxifen-sensitive ZR-75-1 
breast cancer cell line. It also engenders anchorage-independent proliferation in the 
absence of estrogens, while the parental cells are unable to do so (1). Analysis of our 
array data (5) and published array data (6, 7) indicated that BCAR4 expression is pres-
ent in approximately 10% of breast cancers. These observations prompted us to further 
characterize this gene for elucidating its relevance in endocrine resistance.
materIals and methods
Cell lines and culture conditions
Cell culture was performed as described previously (2). ZR-75-1 (8) cells were cultured 
in RPMI 1640 medium (Invitrogen, Breda, the Netherlands) supplemented with 10% 
heat-inactivated bovine calf serum (standard medium) (Hyclone, Logan, UT) and 1 nM 
17β-estradiol (E2) (Sigma-Aldrich Chemie, Zwijndrecht, The Netherlands). MCF7 and 
COS-1 cell lines were cultured in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal calf serum (Sigma-Aldrich Chemie).
Generation of constructs and cell lines
FLAG tags with amino acid sequence N-DYKDDDDK-C were fused to BCAR4 via poly-
merase chain reaction. The N-terminal tag, starting with a Kozak sequence, was fused in-
frame to the BCAR4 protein. Hence, the original initiator methionine of BCAR4 was not 
retained in this construct. The C-terminal tag, including a stop codon, was fused to the 
end of the coding sequence. ZR-75-1 cells containing FLAG-tagged BCAR4 constructs 
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were generated using retroviral infection as described before (1). In brief, DNA of FLAG-
tagged BCAR4 constucts were cloned into the LZRS-IRES-Neo expression vector (9) and 
viral particles were produced. ZR-75-1 cells were infected with these particles and after 
selection with G418 (Invitrogen), pools of construct-containing cells were obtained. 
Previously generated ZR/BCAR4 (wt) and ZR/LZRS cells were used as controls (1).
Monkey-BCAR4 DNA fragments were retrieved from rhesus-monkey genomic DNA, 
isolated from blood, and DNA of the COS-1 cell line (African green monkey) using PCR 
and BCAR4-specific primers (forward: TCACCATGTACCAACCTATCC, reverse: ACAAT-
GCTCAGGAGACTTAG, nested forward: CCATGTACCAACCTATCCAAAC, nested reverse 1: 
CAGGAGACTTAGTTCCAAAGACG, nested reverse 2: AGACGAAGATGCCAGGGTTC). PCR 
fragments were cloned into the pCR 2.1-TOPO vector (Invitrogen), sequenced, and subse-
quently transferred into the LZRS-IRES-Neo expression vector. The expression constructs 
were transfected into ZR-75-1 cells, in duplicate, using FuGENE 6 (Roche Diagnostics, 
Almere, The Netherlands). After selection with G418 (Invitrogen) resistant colonies were 
pooled. We used cells containing empty vectors as controls.
Proliferation assays
Pools of ZR/BCAR4, ZR/LZRS, MCF7/BCAR4, and MCF7/LZRS cells were harvested by 
trypsinization and counted with a Coulter Z1 cell counter (Coulter Electronics Ltd, Lu-
ton, UK). Subsequently, 3.5x105 cells were plated in triplicate in 25 cm2 tissue culture 
flasks (Corning, Schiphol, The Netherlands). Experimental medium containing 100nM 
ICI182,780 (Zeneca, Pharmaceuticals, Macclesfield, UK) was changed twice a week. Cells 
were trypsinized, counted and replated in fresh medium at the initial density once a 
week.
Pools of ZR/BCAR4 N-terminal FLAG-tagged and C-terminal FLAG-tagged cells were 
trypsinized and counted with a counting chamber. 7x105 cells were plated in 25 cm2 
tissue culture flasks (Corning) in triplicate. Experimental medium containing 1µM 4-hy-
droxytamoxifen (OH-TAM) (Sigma-Aldrich Chemie) was changed twice a week. Cells 
were trypsinized, counted and replated in fresh medium at the initial density at days 10, 
21, and 30.
ZR/BCAR4 and ZR/LZRS control cells were seeded in 96-wells plates at a density of 5000 
cells/well in a final volume of 200µl. The media contained increasing concentrations of 
OH-TAM (from 100pM to 10µM), raloxifene hydrochloride (Sigma-Aldrich Chemie) (from 
100pM to 10µM), E2 (from 1pM to 10 nM) and BCS (from 0.1% to 20%) or 1% ethanol 
or 0.1% DMSO as vehicle controls. For each concentration and time point cells were 
plated in six fold. After 4 and 6 days of culture at 37˚C 10µl of the proliferation reagent 
WST-1 (Roche Diagnostics) were added to each well, and the cells were returned to the 
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incubator for one hour. Absorbance was determined at 405 nm with a Multiskan Ascent 
microplate photometer (Thermo Fisher Scientific, Breda, The Netherlands).
Pools of ZR-75-1 cells with rhesus monkey BCAR4 (ZR/RM) or African green monkey 
BCAR4 (ZR/AGM) expression constructs were harvested and plated in fifteen 25 cm2 
tissue culture flasks (Corning) with standard medium containing 1µM OH-TAM at a den-
sity of 1.5x105 cells/flask. ZR-75-1 cells with empty vectors were used as controls. At days 
4, 7, 11, and 14 the cells were trypsinized and counted using a Coulter Z1 cell counter 
(Coulter Electronics Ltd) in triplicate.
ZR-75-1 cells and the derived transfectants containing BCAR1 (10), BCAR3 (11), EGFR 
(2) and BCAR4 (1) were seeded into 96 wells plates at a density of 1000 to 2500 cells 
per well in standard medium. After two days, serial dilutions of drugs inhibiting EGFR 
(AG1478 and PKI166), MEK (U0126), MAPK14 (SB203580), SRC (PP2), and PI3K (LY29400) 
were added. Cultures were supplemented with E2, OH-TAM or EGF in final concentrations 
of 1nM, 1µM and 10 ng/ml respectively. After five days, MTT reagent (5 mg/ml in PBS) 
was added and incubated for maximally two hours at 37oC as described previously (2) . 
Formazan production was measured using a Multiskan Ascent microplate photometer. 
Absorbance was corrected for background, averaged and normalized to the control 
cultures. All drug concentrations were tested at least in triplicate wells and the assays 
were performed in duplicate (replicated at least once). IC50 values were calculated from 
the dose response curves. For comparison, the lowest IC50 value for a particular drug 
was set at 1.0 and used to assess the relative sensitivities of the different cell lines and 
culture conditions.
Cellular localization of BCAR4
ZR-75-1 cell lines expressing FLAG-tagged BCAR4 proteins were cultured on LAB-TEC mi-
croscope slides (Nalge-Hunc Int., Rochester, NY, USA) and fixed with methanol at -20°C. 
Protein localization was determined by light microscopy and immunofluoresence using 
anti-FLAG M2 (Amersham Biosciences Benelux, Roosendaal, The Netherlands) and Cy3-
labeled goat anti-mouse (Jackson Immuno Research Labs, Suffolk, UK) antibodies. For 
detection of FLAG-tagged BCAR4 proteins on western blots we also used Anti-FLAG M2 
(Amersham Biosciences Benelux) as primary antibody and HRP-conjugated anti-mouse 
Ig (Amersham Biosciences Benelux).
Xenograft formation in nude mice
ZR/BCAR4 and ZR/LZRS cells were harvested and resuspended in fresh culture medium 
and matrigel (5:1) (Collaborative Research, Bedford, MA, USA). Cell suspensions were 
subcutaneously injected (2x106 cells /site) under the mammary fat pad region of eight 
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6-week old female nu/nu nude mice, at the right and left 4th nipple. The developing tu-
mors were measured twice weekly.
results
Ectopic expression of BCAR4 induces resistance to the pure antiestrogen 
ICI182,780 in ZR-75-1 and MCF7 breast cancer cells.
Previously we showed, that ectopic expression of BCAR4 enables ZR-75-1 cells to prolif-
erate in the presence of OH-TAM (1). To further establish the role of BCAR4 in antiestro-
gen resistance, we investigated whether the same result could be obtained in a differ-
ent estrogen-dependent cell line, MCF7, and in the presence of the pure antiestrogen 
100nM of ICI182,780. We generated MCF7/BCAR4 cells and tested these, together with 
ZR/BCAR4 cells, for proliferation in the presence of ICI182,780. As shown in Figure 5.1A, 
ZR/BCAR4 cells were fully resistant to this pure antiestrogen. Similarly, MCF7/BCAR4 cells 
were able to proliferate in the presence of ICI182,780 while vector-control cells were 
growth inhibited (Figure 5.1B). From these results it is shown that ectopic expression 
of BCAR4 transforms both breast cancer models from an antiestrogen-sensitive to an 
antiestrogen-resistant state.
Proliferation of BCAR4 cells is dependent on serum but not on estradiol.
We compared the ability of ZR-75-1 and ZR/BCAR4 cells to proliferate in medium con-
taining different concentrations of bovine calf serum (BCS), 17β-estradiol (E2), and the 
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Figure 5.1
BCAR4 induces resistance to the pure antiestrogen ICI182,780 in ZR-75-1 (A) and MCF7 (B) cell lines. Cells containing BCAR4 and vector control 
cells were cultured in medium containing 100nM of ICI182,780. At the timepoints indicated the cells were counted and replated at the initial 
density. Cumulative cell numbers and SDs are presented.
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antiestrogens OH-TAM and raloxifene. As shown in Figure 5.2A, the BCAR4 cells remained 
dependent on BCS for proliferation. In contrast, addition of E2 up to 100pM caused only 
marginal growth stimulation in ZR/BCAR4 cells, while proliferation of ZR-75-1 cells 
strongly depended on the addition of E2 (Figure 5.2B). No significant growth inhibition 
of ZR/BCAR4 cells was obtained by addition of OH-TAM up to 1µM (Figure 5.2C) or ralox-
ifene up to 100nM (Figure 5.2D). Inhibition of proliferation at higher concentrations may 
be due to toxicity of the drugs. No significant alteration of growth of both cell lines was 
observed by the addition of vehicle (ethanol or DMSO at a final concentration of 1% and 
0.1% respectively) alone.
BCAR4 is highly conserved in primates, but not in rodents
A highly conserved homologous BCAR4 gene is found only in primates among the 
genomes presently sequenced. BLAST searches revealed a 100% similarity between hu-
man and chimpanzee BCAR4 and a 93% similarity between human and rhesus monkey 
BCAR4. BLAST searches failed to identify a conserved BCAR4 homologue in other spe-
cies including mouse and rat. To compare the function of two primate homologues with 
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Figure 5.2
Dose-dependent effect of various factors on the proliferation of ZR/BCAR4 cells. ZR/BCAR4 and ZR/LZRS cells seeded in 96-well plates were cultured 
with various concentrations of BCS, E2, OH-TAM, and raloxifene. Cell viability was determined using the WST-1 assay on day 6. Proliferation of 
ZR/BCAR4 cells is dependent on serum components (A). No dose-dependent effects on BCAR4 cell proliferation were seen after addition of E2 (B) 
(whereas proliferation of the vector control cells is strongly stimulated by E2), OH-TAM (up to 1 μM) (C) or raloxifene (up to 10μM) (D). Similar 
curves were obtained at day 4.
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the human BCAR4, we retrieved the BCAR4 sequences from rhesus monkey and African 
green monkey DNA using PCR and generated expression constructs. BCAR4 protein 
sequences of rhesus monkey and African green monkey were closely related to each 
other and showed 93% similarity to the human protein (Figure 5.3). Proliferation assays 
showed that ZR-75-1 cells containing expression constructs with BCAR4 derived from 
rhesus monkey (Figure 5.4A) and African green monkey (Figure 5.4B) were also able to 
proliferate in the presence of OH-TAM.
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Figure 5.3
Alignment of primate BCAR4 proteins. The human BCAR4 protein is 100% identical to chimpanzee BCAR4 protein (acc nr XM_510822). Rhesus 
monkey and African green monkey (AGM) sequences were aligned with the Clustal W multiple sequence alignment software tool. Amino acid 
identities (93%) are shown as dots. The positions of the signal peptide (a.a. 1-41, solid line) predicted using the SignalP 3.0 Server, and of the 
transmembrane domains (a.a. 27-46 and 59-77, dashed line) as predicted by TMpred are shown above the sequence.
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Figure 5.4
Primate homologues of BCAR4 induce OH-TAM-resistant proliferation. Pools of ZR-75-1 cells containing expression constructs with rhesus monkey 
and African green monkey BCAR4 (ZR/RM and ZR/AGM respectively) were plated in 15 culture flasks with medium containing OH-TAM. At the 
timepoints indicated cells were counted in triplicate. Cell numbers and SDs are presented. A. proliferation curves of cells containing rhesus monkey 
BCAR4. B. proliferation curves of cells containing African green monkey BCAR4.
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Subcellular localization of BCAR4
To elucidate possible functions of BCAR4, we examined the subcellular localization of 
the BCAR4 protein. A fusion protein was generated consisting of the BCAR4 polypep-
tide and a FLAG-tag at the N-terminal or C-terminal sites. ZR-75-1 cell lines expressing 
FLAG-tagged BCAR4 proteins were labeled with appropriate primary and secondary 
antibodies. Fluorescence light microscopy revealed that the C-terminal FLAG-tagged 
BCAR4 protein was localized to the cytoplasm, possibly to the Golgi apparatus and to 
the endoplasmatic reticulum, and to a lesser extend to the secretory vesicles and the 
cell membranes (Figure 5.5A). The N-terminal FLAG-tagged BCAR4 protein was localized 
to the cell membranes and to a lesser extent to the cytoplasm (Figure 5.5B). In control 
cell cultures no fluorescent signal was observed. Production of the N-terminal and C-
terminal FLAG-tagged BCAR4 proteins was confirmed by immunoprecipitation with 
antibodies directed against the FLAG tag and western blot analysis (Figure 5.6).
To test whether the fusion of the FLAG-tags to BCAR4 influenced the proliferation 
capacity of the cells in the presence of OH-TAM, growth curves were generated. The cell 
line expressing N-terminal FLAG-tagged BCAR4 protein was able to proliferate efficiently 
in the presence of OH-TAM, but the proliferation rate of cells with the C-terminal FLAG-
tagged BCAR4 protein appeared reduced as compared to the wild-type BCAR4 (Figure 
5.7)
 
  
Figure 5.5
Subcellular localization of FLAG-tagged BCAR4 proteins. ZR-75-1 cell lines expressing FLAG-tagged BCAR4 proteins were cultured on microscope 
slides, fixed, and labeled with primary anti-FLAG and secondary Cy3-labeled antibodies. Fluorescence light microscopy revealed localization of 
C-terminal (3’) FLAG-tagged BCAR4 protein in the cytoplasm (A). N-terminal (5’) FLAG-tagged protein was predominantly localized to the cell 
membranes (B).
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Figure 5.6
Detection of FLAG-tagged BCAR4 proteins. Western blot analysis showed production of C-terminal (3’) and N-terminal (5’) FLAG- tagged proteins. 
Cells containing an empty expression vector were used as control (C).
Figure 5.7 
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Figure 5.7
FLAG-tagged BCAR4 proteins are still able to transform ZR-75-1 cells to an antiestrogen-resistant phenotype. Cells with BCAR4 protein fused to a 
FLAG-tag at the C-terminal (3’) or N-terminal (5’) ends were cultured in medium containing OH-TAM. At the timepoints indicated the cells were 
counted and replated at the initial density. Cumulative cell numbers and SDs are presented. Proliferation of cells containing C-terminal FLAG-
tagged BCAR4 protein was reduced.
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BCAR4 promotes xenograft tumor formation in nude mice
Previously we determined that over-expression of BCAR4 induces anchorage-inde-
pendent transformation of ZR-75-1 cells (1). Therefore, we speculated that this gene 
might be able to induce tumor formation in nude mice. To test their tumorigenicity, 
2x106 empty vector containing ZR/LZRS control cells, and ZR/BCAR4 cells were injected 
into the mammary fat pads of the fourth right and left nipple of female mice. Within 
two weeks, three out of five mice with ZR/BCAR4 xenografts developed tumors on both 
sides (Figure 5.8A). One out of five mice had tumor formation on only one side and in 
one mouse no tumors were detected within 6 months. ZR/LZRS injected mice failed to 
develop any tumors over a period of 6 months follow-up (Figure 5.8B). In the presence 
of an estrogen release pellet, injection of both ZR/LZRS and ZR/BCAR4 cells caused tu-
mor formation in these mice (data not shown). These results show, that ZR/BCAR4 cells 
acquired the capability to drive tumor formation without addition of estrogen.
BCAR4 and the MAPK pathway
Comparing cell proliferation with other tamoxifen-resistant variants of ZR-75-1 cells as-
sessed the sensitivity of the BCAR4 cells to several types of intracellular-signaling inhibi-
tors. The effects of the drugs on proliferation capacity were measured with MTT under 
normal culture conditions (estrogen supplemented) and under selective conditions 
(in the presence of the anti-estrogen OH-TAM). The most prominent inhibitory effects 
were noted in the EGFR transfected cells when stimulated with its ligand EGF (Table 
5.1). BCAR4 cells showed high sensitivity for the MAPK14 (p38) inhibitor under estrogen 
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Figure 5.8
ZR/BCAR4 cells induce tumor formation in nude mice. The mice were injected with ZR/BCAR4 cells or ZR/LZRS control cells in the mammary fat pad 
of the fourth left and right nipples. A. Four out of five mice injected with ZR/BCAR4 cells developed rapidly growing tumors. B. None of the mice 
injected with ZR/LZRS cells showed any tumor formation.
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conditions and were even more sensitive under OH-TAM conditions. In contrast, inhi-
bition of PI3K or SRC was least effective on proliferation of BCAR4 cells, although the 
differences are subtle.
dIscussIon
BCAR4 has previously been identified in a functional screen for genes responsible for 
tamoxifen resistance. We showed that BCAR4 causes tamoxifen resistance in ZR-75-1 
cells, and that cells expressing the gene were transformed to an anchorage-independent 
phenotype (1). In this study, we demonstrated that ectopic expression of BCAR4 also 
supports proliferation in the presence of the pure antiestrogen ICI182,780 (Faslodex/Ful-
vestrant) and raloxifene, and in another estrogen-dependent human breast cancer cell 
line, MCF7. These results indicate that the cells are no longer dependent on estrogens 
for their proliferation, in contrast to the parental cell line. However, the BCAR4 cell line 
still required components present in the bovine serum BCS for proliferation.
The amino acid sequence of BCAR4 does not reveal conserved protein domains, 
with the only exception of a putative anchor signal and two transmembrane domains, 
indicating that the protein might be localized to cell membranes. These features have 
been retained in the rhesus and African green monkey BCAR4 peptides (http://www.
ch.embnet.org/software/TMPRED_form.html, http://www.cbs.dtu.dk/services/SignalP/). 
To explore the cellular localization of BCAR4, we generated BCAR4-FLAG-tagged fusion 
proteins. We investigated if ZR-75-1 cells, stably expressing these fusion proteins were 
still able to proliferate in the presence of OH-TAM. Although tags have been added to 
Table 5.1 Relative Sensitivity to small molecule inhibitors#.
zr-75-1 bcar1 bcar1 bcar3 bcar3 bcar4 bcar4 egfr egfr
target drug e2 e2 oh-t e2 oh-t e2 oh-t e2 oh-t/
egf
pI3k ly294002 1.8 1.5 1.5 1.5 1.0 3.0 3.8 2.6 7.5
src pp2 5.5 3.8 2.7 2.4 1.0 5.0 7.2 4.7 7.3
mapk14 sb203580 4.3 5.6 5.0 4.0 1.9 2.1 1.0 4.3 1.4
mek u0126 nd 1.0 1.0 1.0 1.8 1.8 1.8 1.0 7.9
egfr ag1478 nd 18.5 18.5 18.5 18.5 13.0 12.0 26.5 1.0
# Average (at least two independent experiments) sensitivities of cell lines for a particular drug are given relative to the most sensitive cell line 
IC50 = 1.0. ND= not determined.
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the BCAR4 protein, the cells still have an antiestrogen-resistant phenotype. However, the 
proliferation of cells containing the C-terminal FLAG-tagged protein appeared reduced, 
as compared to the wild-type BCAR4, suggesting functional interference. Fluorescence 
light microscopy revealed that the fusion proteins were localized in the cytoplasm and 
the cell membranes. Localization to the cell membranes was predominantly observed 
with the N-terminal FLAG-tagged construct and in lesser extent with the other tagged 
construct. These results are supported by the presence of the putative signal anchor and 
transmembrane domains. Cells expressing the C-terminal FLAG-tagged protein showed 
an accumulation of BCAR4 protein in the cytoplasm, possibly in the Golgi apparatus and 
the endoplasmatic reticulum. However, the presence of the transmembrane domains 
suggests that the protein may be localized on the cell membrane instead of the cyto-
plasm. This and the reduced growth advantage of the cells expressing the C-terminal 
FLAG-tagged protein in the presence of tamoxifen indicate that the protein accumula-
tion in the cytoplasm might be artificial due to disturbance of the protein structure at the 
C-terminal side. It has previously been reported that addition of a tag to the C-terminus 
of a protein may alter its subcellular localization in comparison to the native protein (12). 
To actually visualize the localization of the original protein without a tag, BCAR4 specific 
antibodies are needed and must be generated.
The BCAR4 protein has well conserved homologues in the chimpanzee (100% identi-
cal), the rhesus monkey (93% identical), and the African green monkey (93% identical). 
Proliferation assays showed that these homologues are still able to transform ZR-75-1 
cells into an OH-TAM resistant phenotype. The absence of the gene in non-primate spe-
cies may indicate that BCAR4 has emerged as a new gene during the primate evolution. 
Johnson et al. reported that new gene families may have been positively selected during 
the emergence of humans and African apes and that a small fraction of human genes 
may not possess orthologues in the genomes of model organisms, such as the mouse 
(13). Although primate-specific genes are rare, some have been identified. For example, 
analyses of the chromosome 21 gene content revealed a small proportion of (possible) 
primate-specific genes (14, 15). Furthermore, the primate-specific Ku86 Autoantigen 
Related Protein-1 (KARP-1) and Coordinated Expression to IRXA2 (CEI) genes have been 
identified (16, 17).
To explore whether BCAR4 is able to form tumors in vivo, female nude mice were in-
jected in the mammary fat pad with BCAR4 expressing cells. Eighty percent of these 
mice developed rapidly growing tumors versus none of the control mice. The ZR/LZRS 
control cells only induced tumor development in the presence of an estrogen-release 
pellet. These results show that BCAR4 induces tumor growth in vivo independent of ad-
ditionally administered estrogens.
In recent years, many small-molecule inhibitors of signaling components have been 
identified and used for research purposes and for clinical applications (18-20). Our pro-
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liferation assays with small-molecule inhibitors indicated that MAPK14 (p38) might play 
a role in BCAR4 signaling, because ZR/BCAR4 cells show a relatively higher sensitivity 
to the MAPK14 inhibitor. However, we have to remain cautious in drawing conclusions, 
because many small-molecule inhibitors exhibit cross reactivity with other related (and 
probably non-related) target molecules (21). In order to deduce unknown signaling 
routes from the cell-growth inhibitory effects of these drugs, adequate controls are 
essential. Independent validation of our results using an independent inhibitor against 
MAPK14 may shed some light on the actual contribution of MAPK14 in BCAR4 signal-
ing.
In conclusion, BCAR4 is a transforming gene with oncogenic potential that makes 
breast cancer cells independent of estrogen stimulation. Our data suggest that BCAR4 
signaling activates the MAPK pathway which has been demonstrated to be involved in 
antiestrogen resistance before (1, 22). CDNA array comparative genomic hybridization 
(CGH) on a panel of breast tumors revealed amplification of the 16p13 region contain-
ing BCAR4 (23). Gene amplification is one of the mechanisms underlying activation of 
oncogenes (24), and has previously been associated with ERBB2-mediated antiestrogen 
resistance (25). Thus, amplification and/or over-expression of BCAR4 might stimulate 
antiestrogen-resistant tumor progression in breast cancer patients. SAGE data (http//
bioinfo.amc.uva.nl/HTMseq/), EST profiles (www.ncbi.nlm.nih.gov/UniGene/ESTProfi-
leViewer.cgi?uglist=Hs.24611), and different sets of array data (5-7) have shown so far 
that BCAR4 is only expressed in normal human placenta and embryonic tissue, and in 
breast cancer. Therefore targeting this gene would specifically affect the tumors express-
ing it, indicating the potential clinical value of this gene in breast cancer therapy.
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Tamoxifen is the most extensively used drug in the treatment of breast cancer. It has been 
used in the clinic during the last four decades and has shown to be successful in preven-
tion of breast cancer, as adjuvant therapy, and as a treatment of metastatic disease (1, 
2). Tamoxifen has shown the ability to reduce recurrences of the cancer and to prolong 
life. However, despite the success of tamoxifen therapy, the patients eventually develop 
resistance to the drug, resulting in breast cancer progression. To overcome tamoxifen 
resistance or to develop new (patient-tailored) treatment strategies, it is necessary to 
understand the underlying mechanisms. The aim of the experimental work described in 
this thesis was to identify genes involved in tamoxifen resistance.
retrovIral transductIon of cdna lIbrarIes
For identifying genes responsible for tamoxifen resistance in human breast cancer 
we used retroviral transduction of cDNA libraries in ZR-75-1 cells. Unlike profiling 
approaches like microarray analysis and serial analysis of gene expression (SAGE), this 
technique allows the establishment of causal relationships between gene overexpres-
sion and tamoxifen resistance, rather than just correlation. As described in chapter 2, we 
uncovered 7 genes to cause tamoxifen resistance in the ZR-75-1 breast cancer cell line. 
Furthermore, 18 genes were assigned as candidates and would require further valida-
tion to establish their role in tamoxifen resistance. From these experiments, it is clear 
that inhibition of cell proliferation in the presence of tamoxifen may be deregulated by 
enhanced expression of multiple different genes.
Introduction of cDNA libraries may result in overexpression of the genes correspond-
ing to the cDNAs inserted in the target cells. Biological effects of loss-of-gene function 
are generally not detected using this strategy. The consequences of gene loss may be 
assessed by RNA interference (RNAi) which has been employed to knock down specific 
transcripts (3, 4). Similar to the cDNA libraries, RNAi libraries can be introduced into the 
cells to perform large-scale loss-of-function screens. Several genome-wide RNAi librar-
ies in different vector systems (5) have become available, but there are still technical 
challenges to overcome. Short hairpin RNA (shRNA) and microRNA-adapted short hair-
pin RNA (shRNAmir) processing is rate limited because of their endogenous processing 
by Drosha and Dicer resulting in partial knockdown levels. This may also be a favorable 
situation because they may have potentially less concentration-dependent off-target 
effects as seen with short interfering RNAs (siRNAs) (5). However, off-target effects can-
not be ruled out and have to be considered. Furthermore, large-scale RNAi screens may 
produce a lot of false positives (6). Despite these hurdles, knock-down strategies may be 
useful to obtain further insight into the mechanisms of tamoxifen resistance.
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genes assocIated wIth tamoxIfen-therapy faIlure In breast cancer 
patIents
FGF17 was identified as one of the genes having a causative role in tamoxifen resistance 
of ZR-75-1 breast cancer cells (chapter 2). To assess whether this gene or the FGF recep-
tors (FGFR) 1, 2, 3 and 4 are associated with clinical outcome of tamoxifen therapy in 
breast cancer patients, mRNA levels of these genes were measured in primary breast 
tumors using quantitative RT-PCR. For all patients extensive clinical follow-up was 
available. Chapter 3 describes a clinical association of FGFR4 with tamoxifen resistance 
in patients with metastatic breast cancer. High levels of FGFR4 mRNA predict a poor 
therapy outcome. However, no association between FGF17 and tamoxifen therapy was 
observed.
FGF17 was recovered from retroviral transduction experiments with a human brain 
tissue cDNA library (chapter 2). EST expression profiling and SAGE analysis showed that 
FGF17 is predominantly expressed in embryonic and brain tissue. This indicates that the 
type of genes recovered from these kind of experiments can strongly depend on the 
tissue source, gene expression levels and the quality of the cDNA library. The absence of 
FGF17 in breast (cancer) tissue may explain its lack of association with failure of tamox-
ifen therapy. However, it is strongly suggested that the pathway activated by FGF17 may 
play an important role in resistance. FGF17 was recently found to mainly activate FGFR4 
in epithelial lineages (7), supporting the theory that activation of FGFR4 is responsible 
for causing tamoxifen resistance in ZR-75-1 breast cancer cells. FGF17 forms a subfamily 
with FGF8 and FGF18 (8). Expression levels of FGF8 were shown to be higher in breast 
cancer than in normal breast tissue (9). It would therefore be interesting to assess 
whether FGF8 has a predictive value for the type of response to tamoxifen treatment.
In our quantitative RT-PCR experiments we did not take into account the splice vari-
ants of the genes involved, like of FGFR1, 2, and 3. Splice variants may have different 
effects on therapy outcome and this has to be considered in future research. Similarly, 
particular SNPs may play a role in gene activity. Therefore studying SNPs in de genes 
identified may provide insight into the mechanisms resulting in overexpression of these 
genes.
bcar4 a novel gene causIng tamoxIfen resIstance
Retroviral transduction of a human placenta cDNA library into ZR-75-1 breast cancer 
cells revealed, amongst others, a novel gene designated BCAR4 (chapter 2). Very little 
was known about this gene as it had no homologues in non-primates or typically con-
served protein domains. Only a signal anchor and two transmembrane regions were 
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predicted in the protein sequence. SAGE data and EST profiling indicated that it was 
expressed in human placenta and embryonic tissue. In addition, relative high expression 
of BCAR4 was observed in a subset of breast-cancer patients having lymph node me-
tastasis at diagnosis and therefore a worse prognosis. In chapter 5 of this thesis further 
characterization of this gene is described.
Ectopic expression of BCAR4 resulted in proliferation of ZR-75-1 and MCF7 breast can-
cer cell lines in the presence of antiestrogens, indicating a causative role for this gene 
in the transformation of the cells from an antiestrogen-sensitive to an antiestrogen-
resistant phenotype. ZR-75-1 cells, transfected to express BCAR4, produced tumors in 
nude mice in the absence of exogenous estrogen, while the parental cells were unable 
to do so. This establishes the transforming properties of BCAR4.
Quantitative RT-PCR on a large series of breast tumors may elucidate whether this 
gene also has predictive or prognostic values in breast cancer. In addition, generation of 
transgenic BCAR4 mouse models may shed some light on its role in tumor development 
and progression. To explore the potential of BCAR4 as a target in breast cancer therapy, 
it is necessary to further unravel its function and biological mechanism. Preliminary lo-
calization experiments with FLAG-tagged BCAR4 proteins showed their presence in the 
cytoplasm and to lesser extent on the cell membranes. Immunohistochemical analyses 
with suitable antibodies against BCAR4 and co-localization of the protein with differ-
ent compartment and organelle-tracking dyes may assess localization of the wild-type 
protein. Determining the cellular localization of the protein may provide insight in its 
functional role.
Preliminary proliferation assays with small-molecule inhibitors indicated that MAPK14 
(p38) may play a role in BCAR4 signaling. Independent validation of these assays may 
establish BCAR4 involvement in the well-known MAPK pathway. Further details about 
the biological mechanism of BCAR4 may be provided by knockdown experiments in 
various cell models, and identification of potential interaction partners of the protein 
using immunoprecipitation and mass spectrometry.
pathway analysIs
Ingenuity Pathway Analysis, KEGG, and literature studies were used to study the 7 genes 
causing tamoxifen resistance and 18 candidate genes recovered from our functional 
screen described in chapter 2. In addition, FGFR4 and TSC22D1, which were described to 
be associated with tamoxifen-therapy failure in breast cancer patients in chapters 3 and 
4, were included. Figure 6.1 shows a simplified network of the genes described in this 
thesis, based on current knowledge. Three genes acetylserotonin methyltransferase-like 
(ASMTL), claudin 23 (CLDN23), and KIAA0513 were not eligible for network analysis. The 
96
Chapter 6
results display a prominent role for growth factor signaling genes and their downstream 
targets in the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-ki-
nase (PI3K)/AKT pathways. Indeed, these pathways have previously been reported in 
laboratory and clinical studies: elevated levels of NRG1, EGFR, ERBB2, and high levels 
of phosphorylated AKT, MAPK1 (ERK2), JNK, and MAPK14 (p38) were associated with 
tamoxifen resistance (10-21). In conclusion, pathway analysis shows that the genes 
identified in our functional screen for tamoxifen resistance can be placed in a network 
together with genes of pathways already known to play a prominent role in tamoxifen 
resistance.
Figure 6.1 
 
Figure 6.1
A simplified network of the genes described in this thesis and the genes linked to them. The results display a central role in tamoxifen resistance 
for genes involved in growth factor signaling and their downstream components in the MAPK and PI3K/AKT pathways.
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future perspectIves
From the results in this thesis, it has become clear that functional profiling strategies 
may identify a variety of genes as causative for tamoxifen resistance. Because of their 
causative nature, these genes would provide potential targets for treatment of breast 
cancer patients resistant to tamoxifen therapy. However, not all of the genes will have 
an equally important function in tamoxifen resistance in patients as they do in vitro. For 
overcoming tamoxifen resistance in patients it is important to identify those genes that 
are causative and are associated with resistance in clinical specimens. Then the next step 
would be to develop and test drugs targeting these genes.
Identification of genes associated with resistance in clinical samples has been as-
sessed by applying high-throughput profiling techniques, using for example cDNA 
microarrays (22). Comparison of the results of these kind of studies with the results of 
functional profiling strategies will provide the best candidate targets for therapy. The 
clinical relevance of two of such genes, TSC22D1 and PSAP, is described in chapter 4 
of this thesis. The mRNA levels of TSC22D1 and PSAP were assessed in a set of primary 
breast tumors with clinical follow-up, and high levels were significantly associated with 
a shorter progression-free survival. Therapy outcome was even worse when patients had 
high mRNA levels of both genes. The clinical significance of these genes in breast cancer 
therapy makes them interesting candidates for future studies. Since their mechanisms 
of action have not been well characterized yet, further studies to elucidate the pathway 
through which these genes may cause tamoxifen resistance are recommended. To this 
end, in vitro models with ectopic expression of either one and both of these genes have 
to be generated. Experiments using microarray profiling will enable pathway analysis, 
possibly providing new drugable targets for therapy.
Another putative treatment target provided by our studies is FGFR4. FGFR4 was also 
demonstrated to be associated with resistance. Establishment of its causative role may 
be obtained by inducing ectopic expression of the gene in a tamoxifen-sensitive cell 
line or knocking out the gene in a FGF17-overexpressing tamoxifen-resistant cell line, 
and monitoring a conversion to tamoxifen insensitivity. Such establishment would make 
FGFR4 a novel potential target for patient-tailored therapy. Patients with breast tumors 
expressing high levels of FGFR4 and thus having a high chance of tamoxifen-therapy 
failure might then be treated with a small-molecule tyrosine-kinase inhibitor targeting 
FGFR4. FGFR inhibitor PD173074 has already been demonstrated to be able to reduce 
proliferation of the FGFR4-overexpressing tamoxifen-insensitive MDA-MB-453 breast 
cancer cell line (23). Further in vitro studies with PD173074 relating to tamoxifen thera-
py, and studies using animal models will be needed to establish its ability to overcome 
tamoxifen resistance. Results confirming this ability in vitro and in vivo would be a good 
basis for subsequent clinical trails.
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It is known, however, that drug interference in important genetic pathways may cause 
serious side effects. Targeting a tumor-specific gene, like BCAR4 seems to be, would 
circumvent this problem. Therefore, further investigation of the biological mechanism 
of BCAR4 and its association with resistance in clinical samples, might provide us with a 
very promising new target for therapy.
concludIng remarks
The results presented in this thesis contribute to the understanding of possible mecha-
nisms causative for tamoxifen resistance in breast cancer. In addition, it was shown that 
these data may lead us to genes that are predictive for tamoxifen resistance in patients 
as well. Due to the broad spectrum of genes involved in resistance, it is clear that it will 
be very difficult to develop a new treatment strategy suitable for all tamoxifen-resistant 
patients. Instead, a combination of various treatment strategies targeting the most 
prominent escape pathways (including AIs, small molecule tyrosine kinase inhibitors, 
etc.) might be used for treatment. Furthermore, increasing the knowledge on mecha-
nisms of resistance may contribute to the development of patient-tailored therapies 
based on the characteristics of the primary tumor in the future.
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summary
Breast cancer is the most common cancer in women in the western world. Since estrogen-
receptor positive breast tumors are often dependent on the female hormone estrogen, 
the antiestrogen tamoxifen is most extensively used in the treatment of breast cancer. 
Tamoxifen treatment inhibits tumor growth in half of the patients having estrogen-
receptor positive tumors. However, the duration of this effect is limited and eventually 
the tumor will become resistant.
chapter 1 generally describes the involvement of estrogens in breast cancer and the 
possible mechanisms of estrogen signaling in human cells. Although nowadays various 
therapeutic agents are available for endocrine therapy, like different SERMs, SERDs, AIs, 
and LHRH agonists, tamoxifen has been the mainstay for treatment of estrogen receptor 
positive breast cancers over the past thirty years. However, resistance to the drug, for 
which multiple mechanisms may be responsible, is an inevitable phenomenon. The aim 
of the research described in this thesis is to unravel the genes responsible for tamoxifen 
resistance in breast cancer.
chapter 2 discusses a rapid functional approach applied for this purpose. Retroviral 
transduction of cDNA libraries in ZR-75-1 breast cancer cells, causing overexpression of 
random genes, revealed 73 genes that may be responsible for tamoxifen resistance. Af-
ter application of stringent selection criteria 7 genes were considered to be responsible 
for tamoxifen resistance in breast cancer cells, and 18 genes were considered to be good 
candidate genes. Furthermore, the novel gene BCAR4 was identified. In addition, it has 
been shown that some of the genes identified in the functional screen had a predictive 
value for tamoxifen therapy in patients with recurrent breast cancer.
In chapter 3 the mRNA levels of FGF17, and FGFR1-4 were assessed in 285 estrogen 
receptor-positive primary breast carcinomas using quantitative PCR. High levels of 
FGFR4 predicted a poor response on tamoxifen therapy and a shorter progression-free 
survival of the patients, independent from the traditional predictive factors.
Comparison of the list of genes revealed by the functional screen described in chapter 
2 with an 81-gene signature derived from a microarray study for revealing genes predic-
tive for tamoxifen response in breast cancer patients, identified two overlapping genes. 
In the study described in chapter 4 mRNA levels of the two genes, TSC22D1 and PSAP, 
were measured in 223 tumors of patients with recurrent breast cancer using quanti-
tative PCR. High mRNA levels of TSC22D1 and PSAP were significantly associated with 
shorter progression-free survival of the patients independent of the traditional predic-
tive factors. Patients with tumors expressing high levels of both genes had the shortest 
progression-free survival. Identification of a genetic pathway in which both of these 
genes play a role, might elucidate possible novel targets for breast cancer therapy.
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chapter 5 describes further characterization of BCAR4, a novel gene causing tamoxifen 
resistance as identified in the functional screen described in chapter 2. It was shown that 
ectopic expression of BCAR4 caused resistance to antiestrogens in two breast cancer cell 
lines and tumor formation in nude mice. The gene is thought to be primate specific, and 
overexpression of the primate homologues also caused tamoxifen resistance of ZR-75-1 
breast cancer cells. Fusion proteins of BCAR4 with FLAG-tags suggest protein localization 
in the cytoplasm and in the cell membrane. Experiments using small-molecule inhibitors 
have shown possible involvement of MAPK14 in the BCAR4 gene pathway. Our results 
suggest a possible role for this pathway in breast cancer progression.
chapter 6 contains a general discussion about the results described in this thesis 
and future perspectives. The results revealed genes involved in tamoxifen resistance. 
Gene pathway analyses have demonstrated that all 7 genes responsible for tamoxifen 
resistance and 18 candidate genes were connected with genes involved in the MAPK 
and AKT pathways. The results suggest an important role for these genetic pathways in 
tamoxifen resistance in breast cancer.
Identifying genes involved in tamoxifen resistance and their corresponding genetic 
pathways is very important for improving diagnosis of breast cancer and enabling 
patient-tailored treatment in the future.
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samenvattIng
Borstkanker is de meest voorkomende kanker bij vrouwen in de westerse wereld. Omdat 
oestrogeen receptor positieve borsttumoren voor hun groei vaak afhankelijk zijn van het 
vrouwelijk hormoon oestrogeen, wordt voor de behandeling veelal het anti-oestrogeen 
tamoxifen gebruikt. Bij de helft van de patiënten met dit soort tumoren blokkeert deze 
behandeling de groei van de tumor. Echter, de duur van dit effect kan sterk variëren en 
na verloop van tijd ontstaan resistente uitzaaiingen.
hoofdstuk 1 is een algemene inleiding, waarin het belang van oestrogenen in 
borstkanker en de mogelijke mechanismen van het oestrogeen signaalpad bespro-
ken worden. Hoewel er tegenwoordig verschillende vormen van hormonale therapie 
beschikbaar zijn in de vorm van SERMs, SERDs, AIs en LHRH agonisten, is tamoxifen 
gedurende de afgelopen 30 jaar de voornaamste behandelingsvorm voor oestrogeen 
receptor positieve borstkanker geweest. Echter, resistentie tegen de therapie, waar ver-
schillende mechanismen voor verantwoordelijk kunnen zijn, is onvermijdelijk. Het doel 
van het onderzoek, beschreven in dit proefschrift, is het identificeren van genen, die 
verantwoordelijk zijn voor tamoxifenresistente groei van borsttumoren.
hoofdstuk 2 beschrijft een snelle aanpak om dit doel te bereiken. Door willekeurige 
genen uit bepaalde weefsels verhoogd tot expressie te brengen in ZR-75-1 borstkan-
kercellen, zijn 73 genen geïdentificeerd die mogelijk verantwoordelijk zijn voor tamoxi-
fen resistentie. Na het toepassen van strenge selectie criteria, heeft dit 7 genen en 18 
kandidaat-genen opgeleverd die borstkankercellen tamoxifen resistent kunnen maken. 
Bovendien is van een aantal van deze genen aangetoond, dat indien de primaire tumor 
een hoge expressie had van de betreffende genen, patiënten minder goed reageerden 
op de behandeling met tamoxifen.
In hoofdstuk 3 is de voorspellende waarde van FGF17 en de FGF receptoren 1-4 voor 
tamoxifentherapie beschreven. Door middel van kwantitatieve RT-PCR zijn in 285 oes-
trogeen receptor positieve primaire borsttumoren de mRNA waarden van deze genen 
gemeten. Hiermee is aangetoond, dat hogere expressie van FGFR4 geassocieerd is met 
een slechtere respons op tamoxifentherapie en een kortere progressievrije overleving 
van de patiënt, onafhankelijk van de traditionele voorspellende factoren.
De lijst van genen, die geïdentificeerd zijn in de experimenten beschreven in hoofdstuk 
2, is vergeleken met een genprofiel van 81 genen met een voorspellende waarde voor 
tamoxifentherapie. Dit genprofiel is gemaakt met behulp van microarrays. Twee genen, 
TSC22D1 en PSAP, zijn via beide methoden geïdentificeerd als genen die gerelateerd 
zijn aan tamoxifen resistentie. In hoofdstuk 4 is beschreven, dat in een serie van 223 
oestrogeen receptor positieve primaire borsttumoren hoge expressie van deze genen 
geassocieerd is met een kortere progressievrije overleving van de patiënt, onafhankelijk 
van de traditionele voorspellende factoren. Hoge expressie van beide genen in dezelfde 
tumor voorspelde een nog kortere progressievrije overleving van de patiënt. Verder on-
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derzoek naar het genetische pad waarin beide genen actief zijn, kan nieuw licht werpen 
op mogelijke nieuwe doelwitten voor de behandeling van borstkanker.
Verder bevond zich onder de 73 geïdentificeerde genen ook een nieuw gen, genaamd 
Breast Cancer Antiestrogen Resistance gene 4 (BCAR4), wat tot dan toe slechts voor-
speld was met behulp van computer analyse. Experimenten beschreven in hoofdstuk 
2 en in hoofdstuk 5 hebben aangetoond dat BCAR4 inderdaad resistentie veroorzaakt 
tegen verschillende anti-oestrogenen in verschillende cellijnen en dat het tumorvor-
ming in naakte muizen stimuleert. Het gen lijkt alleen in primaten voor te komen en 
transfectie van genetische homologen uit de rhesus aap en groene meerkat veroor-
zaakte eveneens tamoxifen resistentie in ZR-75-1 cellen. Fusie-eiwitten van BCAR4 en 
verschillende FLAG-tags suggereren dat het eiwit zich bevindt in het cytoplasma van de 
cel en bij het celmembraan. Experimenten met selectieve molecuulremmers duiden aan 
dat mitogen-activated protein kinase 14 (MAPK14/p38) mogelijk een rol speelt in het 
BCAR4 signaalpad. Onze resultaten ondersteunen een mogelijke rol voor dit pad in de 
progressie van borstkanker.
hoofdstuk 6 omvat een algemene discussie over de resultaten uit het proefschrift 
en bespreekt mogelijkheden voor toekomstig onderzoek. De resultaten hebben genen 
onthuld die betrokken zijn bij tamoxifen resistentie. Door signaalpad analyses uit te 
voeren, is aangetoond dat de 7 genen verantwoordelijk voor tamoxifen resistentie en 
de 18 kandidaat-genen allemaal te verbinden zijn met genen uit de MAPK en AKT sig-
naalpaden. Dit suggereert een belangrijke rol voor deze genetische paden in tamoxifen 
resistentie van borstkanker.
Het identificeren van de genen betrokken bij tamoxifen resistentie en de genetische 
paden waar zij invloed op uitoefenen is van groot belang voor de verbetering van de 
diagnose van borstkanker en voor het in de toekomst toe kunnen passen van een speci-
fieke behandeling van borstkanker voor de individuele patiënt.
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eigenlijk onmisbaar is. Ook ik heb met veel plezier met vele mensen samengewerkt bij 
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dit boekje gebruiken om ieder van hen te bedanken.
In het bijzonder wil ik mijn promotor Wolter Oosterhuis en mijn co-promotor Lambert 
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Dr. Bill Miller, wil ik bedanken voor het kritisch lezen van mijn proefschrift, thank you for 
critical reading of my thesis.
Al mijn (ex-)collega’s van molbiol, het voelt goed om mijn vleugels uit te slaan en weer 
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ik vijf jaar met heel veel plezier mee samengewerkt heb. Allemaal bedankt voor de 
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het afgelopen jaar als collega gehad te hebben en samen te genieten van het park en de 
loempia’s. Ik hoop je nog eens tegen te komen in Dort.
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bedankt voor alles!
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qPCR data en alle adviezen op dat gebied. Iris, Maurice, John M. en Arzu bedankt voor 
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